<SEC-DOCUMENT>0001493152-23-022145.txt : 20230622
<SEC-HEADER>0001493152-23-022145.hdr.sgml : 20230622
<ACCEPTANCE-DATETIME>20230622170134
ACCESSION NUMBER:		0001493152-23-022145
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		19
CONFORMED PERIOD OF REPORT:	20230620
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230622
DATE AS OF CHANGE:		20230622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LifeMD, Inc.
		CENTRAL INDEX KEY:			0000948320
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
		IRS NUMBER:				760238453
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39785
		FILM NUMBER:		231034048

	BUSINESS ADDRESS:	
		STREET 1:		236 FIFTH AVENUE
		STREET 2:		SUITE 400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		(866) 351-5907

	MAIL ADDRESS:	
		STREET 1:		236 FIFTH AVENUE
		STREET 2:		SUITE 400
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CONVERSION LABS, INC.
		DATE OF NAME CHANGE:	20180622

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immudyne, Inc.
		DATE OF NAME CHANGE:	20120514

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMMUDYNE INC
		DATE OF NAME CHANGE:	19950720
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:LFMD="http://lifemd.com/20230620">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_LFMD_lifemd.com_20230620 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20230620_20230620 -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0000948320 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:EntityCentralIndexKey">0000948320</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lfmd-20230620.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-06-20to2023-06-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-20_custom_CommonStockParValue0.01PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:CommonStockParValue0.01PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-202023-06-20_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:SeriesCumulativePerpetualPreferredStock0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-20</xbrli:startDate>
        <xbrli:endDate>2023-06-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_907_edei--DocumentType_c20230620__20230620_zIdEQin5dPr3"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90C_edei--DocumentPeriodEndDate_c20230620__20230620_zKRVPzErcyWb"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 20, 2023</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_905_edei--EntityRegistrantName_c20230620__20230620_ziOklf9j57tj"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:EntityRegistrantName">LIFEMD,
INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20230620__20230620_zrNod9oRaAD3"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityFileNumber_c20230620__20230620_zHoUmD2586q8"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:EntityFileNumber">001-39785</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20230620__20230620_zXhD2UtwWtmb"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:EntityTaxIdentificationNumber">76-0238453</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission
                                            </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
                                            Employer </b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressAddressLine1_c20230620__20230620_zl2ZciG877A8"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:EntityAddressAddressLine1">236
Fifth Avenue</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20230620__20230620_zwQhAbsvm3Xi"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:EntityAddressAddressLine2">Suite 400</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90F_edei--EntityAddressCityOrTown_c20230620__20230620_z69E7PvXLlj8"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:EntityAddressCityOrTown">New
York</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20230620__20230620_z8yT3AgD47z6"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20230620__20230620_zpYvsrxvFYUb"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:EntityAddressPostalZipCode">10001</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices, including zip code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_902_edei--CityAreaCode_c20230620__20230620_zgo4Wa76zhx4"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:CityAreaCode">(866)</ix:nonNumeric></span>
<span id="xdx_909_edei--LocalPhoneNumber_c20230620__20230620_zkArQw2Nxkz4"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" name="dei:LocalPhoneNumber">351-5907</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--WrittenCommunications_c20230620__20230620_zNdiU1Ic6GMi"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--SolicitingMaterial_c20230620__20230620_z9hZxwPY5cxj"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20230620__20230620_zQrNGTJ4QbCe"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20230620__20230620_z2cDO86cSmyg"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20230620__20230620__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_zyI7RqCsjMkj"><ix:nonNumeric contextRef="From2023-06-202023-06-20_custom_CommonStockParValue0.01PerShareMember" name="dei:Security12bTitle">Common
    Stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20230620__20230620__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_zohymauatxTa"><ix:nonNumeric contextRef="From2023-06-202023-06-20_custom_CommonStockParValue0.01PerShareMember" name="dei:TradingSymbol">LFMD</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
    <span id="xdx_90D_edei--SecurityExchangeName_c20230620__20230620__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.01PerShareMember_zgjy5g1MyNv9"><ix:nonNumeric contextRef="From2023-06-202023-06-20_custom_CommonStockParValue0.01PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20230620__20230620__us-gaap--StatementClassOfStockAxis__custom--SeriesCumulativePerpetualPreferredStock0.0001PerShareMember_zPIwaJeGC7y2"><ix:nonNumeric contextRef="From2023-06-202023-06-20_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" name="dei:Security12bTitle">Series
    A Cumulative Perpetual Preferred Stock, $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20230620__20230620__us-gaap--StatementClassOfStockAxis__custom--SeriesCumulativePerpetualPreferredStock0.0001PerShareMember_z6qqUqNGH0Yk"><ix:nonNumeric contextRef="From2023-06-202023-06-20_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" name="dei:TradingSymbol">LFMDP</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
    <span id="xdx_90E_edei--SecurityExchangeName_c20230620__20230620__us-gaap--StatementClassOfStockAxis__custom--SeriesCumulativePerpetualPreferredStock0.0001PerShareMember_zNUofJQo0Xk9"><ix:nonNumeric contextRef="From2023-06-202023-06-20_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20230620__20230620_z5eVVCZGiIqd"><ix:nonNumeric contextRef="From2023-06-20to2023-06-20" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Resignation
of Stefan Galluppi from the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, Stefan Galluppi resigned from the Board of Directors of LifeMD, Inc. (the &#8220;Company&#8221;) effective immediately.
Mr. Galluppi&#8217;s resignation was not due to a disagreement with the Company on any matter relating to its operations, policies or
practices, and he will continue to serve as the Company&#8217;s Chief Innovation Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Appointment
of William J. Febbo to the Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, William J. Febbo was appointed to the Board of Directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Febbo is Chief Executive Officer and a Director of OptimizeRx Corporation (Nasdaq: OPRX). OptimizeRx is a leading provider of digital
point-of-care technology solutions that help patients start and stay on therapy. For more than 25 years Mr. Febbo has built and managed
health services and financial businesses, starting in M&amp;A and international business development at multinational companies. In 1999
he co-founded and subsequently served as Chief Executive Officer of MedPanel, a market intelligence and communication provider to the
life sciences and financial industries. In 2007 MedPanel was acquired by Merriman Capital, where he served as Chief Operating Officer
of investment banking and as Chief Executive Officer of the firm&#8217;s Digital Capital Network. In 2016 Mr. Febbo joined OptimizeRx,
where he helped transform the firm into a leading digital health company enabling care-focused engagement between life sciences organizations,
healthcare providers, and patients at critical junctures throughout the patient care journey. Mr. Febbo serves as a faculty member for
the Massachusetts Institute of Technology linQ program, a collaborative initiative increasing the potential of innovative biomedical
research to benefit society and the economy. He also serves on the board of the United Nations of Greater Boston, a non-profit organization
focused on building a stronger network of global citizens in the Boston area.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with Mr. Febbo&#8217;s appointment to the Board, the Company and Mr. Febbo entered into a Director Agreement, whereby Mr.
Febbo received (i) a grant of 75,000 restricted shares of the Company&#8217;s common stock, with 37,500 restricted shares vesting
immediately and 37,500 restricted shares vesting on the two-year anniversary of the Director Agreement, pursuant to a Restricted
Stock Award Agreement under the LifeMD, Inc. 2020 Equity and Incentive Plan, as amended (the &#8220;Plan&#8221;), and (ii) a stock
option to purchase 37,500 shares of the Company&#8217;s common stock, vesting on the two-year anniversary of the Director Agreement,
pursuant to a Non-Qualified Stock Option Agreement under the Plan. Unvested restricted shares will vest immediately in the event
that Mr. Febbo is removed as a director or not asked to stand for re-election for reasons other than for &#8220;Cause,&#8221; as
defined in the Plan, or immediately prior to the closing of a &#8220;Change in Control,&#8221; as defined in the award agreement.
All unvested options shall be forfeited, but Mr. Febbo shall have the right to exercise vested options for a period of three months
after his departure from the Board, a period which would be extended to 12 months in the case of death or disability. The awards may
be forfeited in the event of Mr. Febbo&#8217;s breach of certain covenants contained in the respective award agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">On May 30, 2023, prior
to his appointment to the Board of Directors, Mr. Febbo entered into a Consulting Services Agreement with the Company, pursuant to which
he provides certain investor relations and strategic business development services, in consideration for 375,000 restricted shares of
the Company&#8217;s common stock, which will vest in quarterly installments from August 30, 2023 through November 30, 2024. Either Party
may, upon 14 days written notice to the other Party, terminate this Agreement at any time for any reason, at which time, any unvested
restricted shares will be forfeited. Unvested restricted shares will vest immediately prior to the closing of a &#8220;Change in Control,&#8221;
as defined in the Consulting Services Agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
5.02 of this Current Report on Form 8-K contains only a brief description of the material terms of and does not purport to be a complete
description of the rights and obligations of the parties to the Consulting Services Agreement, Director Agreement, Restricted Stock Award
Agreement and Non-Qualified Stock Option Agreement, and such description is qualified in its entirety by reference to the full text of
the agreements, which are filed as Exhibits and incorporated by reference into this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01 Other Events</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 20, 2023, the Company issued a press release announcing the appointment of William J. Febbo to its Board of Directors. A copy of
the press release is filed as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="text-align: justify; width: 0.1in">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Agreement, dated June 20, 2023 between LifeMD, Inc. and William J. Febbo</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Stock Award Agreement, dated June 20, 2023, between LifeMD, Inc. and William J. Febbo</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-3.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Qualified Stock Option Agreement, dated June 20, 2023, between LifeMD, Inc. and William J. Febbo</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-4.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Services Agreement, dated May 30, 2023, between LifeMD, Inc. and William J. Febbo</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated June 20, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LIFEMD,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    22, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Eric Yecies</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eric
    Yecies</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Counsel and Chief Compliance Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJyFkE1uwjAQhU/AHUZRlyg46Y+q7GjUoqqhigAhtoYMrUVsR2MnLUfqLTtxCmyQalmyrZn3veeJonE0sy+qRoLN06KAFeqmlh5hgXskNDvkjvz1LQM+F/ihnCdpfHiehLllDbLmPk4et1wIrZ1yWGUgHiapmKS3fMnuBJTzaNTXc2v2qkLjlaxBmgpKsg0p9JKOA2Elv62x+his1khOWZNBEouh/AOpSFJ4t538snRwUBR5NBqHNYpmZNumt2mdtxqea9Ts5QbpZYcou9CTLZHtXd7qlv+vOiyRGvStrEvqR0FYLb3dHUQshEi4uPyUhHPUWySGJCLlPNO/cAMLpnDBwZkHZyAE4hhuBig0PEzXY6/E4yFra4KglLSWdYus+i/IoDr5NJKg65XB8YrfL2FmnxQ= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
DIRECTOR AGREEMENT is made as of June 20, 2023 (the &ldquo;<U>Agreement</U>&rdquo;), by and between LifeMD, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), and William Febbo, an individual with an address of 142 Calle Violeta, San Juan, Puerto Rico 00927
(the &ldquo;<U>Director</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company and the Director desire to enter with respect to the appointment of the Director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Director is willing to serve the Company on the terms set forth herein and in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants contained herein, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Position</U>.
Subject to the terms and provisions of this Agreement, the Director hereby agrees to serve the Company as a member of the Company&rsquo;s
Board of Directors (the &ldquo;<U>Board</U>&rdquo;), upon the terms and conditions hereinafter set forth, provided, however, that the
Director&rsquo;s service on the Board after the next annual stockholders&rsquo; meeting shall be subject to approval by the Company&rsquo;s
stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Duties</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) During
the Directorship Term (as defined herein), the Director shall make reasonable business efforts to attend all Board meetings, serve on
appropriate committees and subcommittees as reasonably requested by the Board, make himself available to the Company at mutually convenient
times and places, attend external meetings and presentations as appropriate and convenient, and perform such duties, services, and responsibilities&mdash;and
have the authority&mdash;commensurate with such position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Director will make reasonable efforts to promote the interests of the Company. The Company recognizes that the Director (i) is or may
become a full-time executive employee of another entity, and that her responsibilities to such entity must have priority and (ii) sits
or may sit on the board of directors of other entities. Notwithstanding the same, the Director will make reasonable efforts to coordinate
her respective commitments so as to fulfill her obligations to the Company and, in any event, will fulfill her legal obligations as a
Director. Other than as set forth above, the Director will not, without prior notification to the Board, engage in any other business
activity which could reasonably be expected to materially interfere with the performance of her duties, services, and responsibilities
hereunder or which is in violation of the reasonable policies established from time to time by the Company and of which the Director
has been provided copies, provided that the foregoing shall in no way limit her activities on behalf of (i) any current or future employer
and its affiliates or (ii) the board of directors of any entities on which she currently sits or hereafter joins. At such time as the
Board receives such notification, the Board may require&mdash;upon a majority vote of the remaining Directors&mdash;the resignation of
the Director if it determines that such business activity does in fact materially interfere with the performance of the Director&rsquo;s
duties, services, and responsibilities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <U>Compensation</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Equity
Compensation</U>. Pursuant to the Company&rsquo;s 2020 Equity and Incentive Plan (the &ldquo;Plan&rdquo;) and any amendments thereto,
the Director shall receive, upon complete execution of this Agreement, a grant of Seventy Five Thousand (75,000) restricted shares of
the Company&rsquo;s common stock, with Thirty Seven Thousand Five Hundred (37,500) shares vesting immediately upon execution of this
Agreement; and an additional Thirty Seven Thousand Five Hundred (37,500) restricted shares vesting on the two-year anniversary of this
Agreement, so long as it has not been previously terminated by the Company. The Director shall also receive a stock option to purchase
Thirty Seven Thousand Five Hundred (37,500) shares of the Company&rsquo;s common stock with an exercise price equal to the closing share
price on the grant date (which shall be the date the Director joins the Board). The stock option shall vest on the two-year anniversary
of this Agreement and shall be governed by the Plan. The foregoing grants of restricted shares and options shall be made on the Company&rsquo;s
customary form of restricted stock award and stock option award for directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Independent
Contractor</U>. The Director&rsquo;s status during the Directorship Term shall be that of an independent contractor and not, for any
purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or
provided to the Director under this Section 3 shall be made or provided without withholding or deduction of any kind, and the Director
shall assume sole responsibility for discharging all tax or other obligations associated therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Expense
Reimbursements</U>. During the Directorship Term, the Company shall reimburse the Director for (i) all reasonable out-of-pocket expenses
incurred by the Director in attending any in-person meetings, provided that the Director complies with the generally applicable policies,
practices, and procedures of the Company for submission of expense reports, receipts, or similar documentation of such expenses, and
(ii) any costs associated with filings required to be made by the Director or any of the entities managed or controlled by the Director
to report beneficial ownership or the acquisition or disposition of securities of the Company. Any reimbursements for material expenses
(as compared to reasonable out-of-pocket expenses of the Director) must be approved in advance by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <U>Directorship
Term</U>. The &ldquo;<U>Directorship Term</U>&rdquo; as used in this Agreement, shall mean the period commencing on the date hereof and
terminating on the earlier of the date of the next annual stockholders meeting or the earliest of the following to occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) the
death of the Director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) the
termination of the Director from her membership on the Board by the mutual agreement of the Company and the Director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) the
removal of the Director from the Board by the majority stockholders of the Company; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) the
resignation by the Director from the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <U>Director&rsquo;s
Representation and Acknowledgment</U>. The Director represents to the Company that her execution and performance of this Agreement shall
not be in violation of any agreement or obligation (whether or not written) that she has with or to any person or entity, including without
limitation, any prior or current employer. The Director hereby acknowledges and agrees that this Agreement (and any other agreement or
obligation referred to herein) shall be an obligation solely of the Company, and the Director shall have no recourse whatsoever against
any officer, director, employee, stockholder, representative, or agent of the Company or any of their respective affiliates with regard
to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <U>Director
Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <U>Unauthorized
Disclosure</U>. The Director agrees and understands that in the Director&rsquo;s position with the Company, the Director has been and
will be exposed to and receive information relating to the confidential affairs of the Company, including, but not limited to, technical
information, business and marketing plans, strategies, customer information, other information concerning the Company&rsquo;s products,
services, promotions, development, financing, expansion plans, business policies and practices, and other forms of information considered
by the Company to be confidential and proprietary, and in the nature of trade secrets. The Director agrees that during the Directorship
Term and thereafter, the Director will keep such information confidential and will not disclose such information, either directly or
indirectly, to any third person or entity without the prior written consent of the Company; provided, however, that (i) the Director
shall have no such obligation to the extent such information is or becomes publicly known or generally known in the Company&rsquo;s industry
other than as a result of the Director&rsquo;s breach of her obligations hereunder and (ii) the Director may, after giving prior notice
to the Company to the extent practicable and lawful under the circumstances, disclose such information to the extent required by applicable
laws or governmental regulations or judicial or regulatory process. This confidentiality covenant has no temporal, geographical, or territorial
restriction. Upon termination of the Directorship Term, the Director will promptly return to the Company and/or destroy&mdash;at the
Director&rsquo;s direction, unless the Company expresses that specific returns are material and necessary&mdash;all property, keys, notes,
memoranda, writings, lists, files, reports, customer lists, correspondence, tapes, disks, cards, surveys, maps, logs, machines, technical
data, other product or document, and any summary or compilation of the foregoing, in whatever form, including, without limitation, in
electronic form, which has been produced by, received by, or otherwise submitted to the Director in the course or otherwise as a result
of the Director&rsquo;s position with the Company during or prior to the Directorship Term, provided that the Company shall retain such
materials and make them available to the Director if requested by him/her in connection with any litigation against the Director under
circumstances in which (i) the Director demonstrates to the reasonable satisfaction of the Company that the materials are necessary to
her defense in the litigation and (ii) the confidentiality of the materials is preserved to the reasonable satisfaction of the Company.
Nothing contained herein shall be deemed to preclude or restrict the Director from making any legally required disclosures or from making
disclosures pursuant to any whistleblower or similar statutory or regulatory regime.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <U>Non-Solicitation</U>.
During the Directorship Term and for a period of one (1) year thereafter, the Director shall not interfere with the Company&rsquo;s relationship
with, or endeavor to entice away from the Company, any person who, on the date of the termination of the Directorship Term and/or at
any time during the one year period prior to the termination of the Directorship Term, was an employee or customer (including those reasonably
expected to be a customer) of the Company or otherwise had a material business relationship with the Company. Notably, Director has pre-existing
relationships, as well as those created through the ordinary course of business, from Director&rsquo;s work with the Boston Children&rsquo;s
Hospital, Harvard Medical School, iSelect Fund, Virtue Foundation, and others&mdash;none of which will be deemed a violation of this
provision or this Agreement now or into the future, so long as there is no malicious intent to violate this Agreement through such pre-existing
relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Non-Compete</U>.
During the Directorship Term and for a period of one (1) year thereafter, without the Board&rsquo;s approval, the Director shall not
in any manner, through any person, firm, or corporation, alone or as a member of a partnership or as an officer, director, stockholder,
investor, or employee of or consultant to any other corporation or enterprise, directly engage in the business of developing, marketing,
selling, or supporting technology to or for businesses in which the Company engages in or in which the Company has an actual intention,
as evidenced by the Company&rsquo;s written business plans created during the Directorship Term, to engage in, within any geographic
area in which the Company is then conducting such business. Nothing in this Section 6 shall prohibit the Director from being (i) a stockholder
in a mutual fund or a diversified investment company or (ii) a passive owner of the outstanding stock of any class of securities of a
corporation, which is publicly traded, so long as the Director has no active participation in the business of such corporation. Notably,
Director has pre-existing relationships with the Boston Children&rsquo;s Hospital, Harvard Medical School, iSelect Fund, Virtue Foundation,
and others&mdash;none of which will be deemed a violation of this provision or this Agreement now or into the future, so long as there
is no malicious intent to violate this Agreement through such pre-existing relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <U>Insider
Trading</U>. The Director understands and acknowledges that the securities of the Company are publicly traded and subject to the Securities
Act of 1933 and the Securities Exchange Act of 1934. As a result, the Director agrees to: (i) refrain from trading in securities of the
Company while in possession of material nonpublic information, (ii) refrain from disclosing any material nonpublic information to anyone
except as permitted in connection with the performance of the Director&rsquo;s duties hereunder or as required by law, and (iii) communicate
to any person who, to the Director&rsquo;s knowledge, receives any material nonpublic information, that such information is material
nonpublic information and that the trading and disclosure restrictions in clause (i) above also apply to such person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <U>Remedies</U>.
The Director agrees that any breach of the terms of this Section 6 would result in irreparable injury and damage to the Company for which
the Company would have no adequate remedy at law. The Director, therefore, also agrees that in the event of said breach or any threat
of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach
and/or continued breach by the Director and/or any and all entities acting for and/or with the Director, without having to prove damages
or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this paragraph
shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, but not
limited to, the recovery of damages from the Director. The Director acknowledges that the Company would not have entered into this Agreement
had the Director not agreed to the provisions of this Section 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) The
provisions of this Section 6 shall survive any termination of the Directorship Term, and the existence of any claim or cause of action
by the Director against the Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement
by the Company of the covenants and agreements of this Section 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <U>Termination
for Cause</U>. The Company may terminate the engagement of the Director if the Board determines&mdash;upon a majority vote of the remaining
Directors&mdash;that the Director has:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) materially
breached any provision hereof or habitually neglected the duties which the Director was required to perform under any provision of this
Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) misappropriated
funds or property of the Company or otherwise engaged in acts of dishonesty, fraud, misrepresentation, or other acts of moral turpitude,
even if not in connection with the performance of the Director&rsquo;s duties hereunder, which could reasonably be expected to result
in serious prejudice to the interests of the Company if the Director was retained as a director;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) secured
any personal profit not completely disclosed to and approved by the Company in connection with any transaction entered into on behalf
of or with the Company or any affiliate of the Company; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) failed
to carry out and perform duties assigned to the Director in accordance with the terms hereof in a manner acceptable to the Board after
a written demand for substantial performance is delivered to the Director which identifies the manner in which the Director has not substantially
performed the Director&rsquo;s duties and provided further that the Director shall be given a reasonable opportunity to cure such failure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of this section, the Director shall not be terminated for Cause without: (i) reasonable notice to the Director setting forth
the reasons for the Company&rsquo;s intention to Terminate for Cause and a reasonable opportunity to cure such situation (if capable
of cure), (ii) an opportunity for the Director, together with counsel, to be heard before the Board, and (iii) delivery to the Director
of a notice of termination from the Board of the Company, finding that, in the good faith opinion of the Board, the Director had engaged
in the conduct set forth above and specifying the particulars thereof in detail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. <U>Indemnification</U>.
The Company agrees to indemnify the Director for her activities as a member of the Board as set forth in the Director and Officer Indemnification
Agreement attached hereto as <B><U>Exhibit A</U></B>. In addition, the Company shall exercise its best efforts to increase the coverage
limit of its directors&rsquo; and officers&rsquo; liability insurance policy (and not otherwise diminish the scope or value of such coverage)
based on market conditions and advice received from the Audit Committee of the Board of Directors and shall thereafter maintain in effect
such coverage with a coverage limit of at least that amount and containing not materially less favorable provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. <U>Non-Waiver
of Rights</U>. The failure to enforce at any time the provisions of this Agreement or to require at any time performance by the other
party hereto of any of the provisions hereof shall in no way be construed to be a waiver of such provisions or to affect either the validity
of this Agreement or any part hereof, or the right of either party hereto to enforce each and every provision in accordance with its
terms. No waiver by either party hereto of any breach by the other party hereto of any provision of this Agreement to be performed by
such other party shall be deemed a waiver of similar or dissimilar provisions at that time or at any prior or subsequent time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. <U>Notices</U>.
Every notice relating to this Agreement shall be in writing and shall be given by personal delivery, overnight delivery, registered or
certified mail&mdash;all with postage prepaid and return receipt requested&mdash;or email with read receipt confirmation, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
to the Company</I>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236
5<SUP>th</SUP> Avenue, 4<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10001</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">Attn:</TD>
    <TD>Justin Schreiber, CEO</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><U>justin@lifemd.com</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>and/or</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Eric H. Yecies, GC &amp; CCO</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><U>eric@lifemd.com</U> or <U>legal@lifemd.com</U></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>If
to the Director</I>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
Febbo</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>wjfebbo@gmail.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
of the parties hereto may change their address for purposes of notice hereunder by giving notice in writing to such other party pursuant
to this Section 10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. <U>Binding
Effect/Assignment</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs,
executors, personal representatives, estates, successors (including, without limitation, by way of merger), and assigns, as applicable.
Notwithstanding the provisions of the immediately preceding sentence, neither the Director nor the Company shall assign all or any portion
of this Agreement without the prior written consent of the other party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12. <U>Entire
Agreement</U>. This Agreement (together with the other agreements referred to herein) sets forth the entire understanding of the parties
hereto with respect to the subject matter hereof and supersedes all prior agreements, written or oral, between them as to such subject
matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. <U>Severability</U>.
If any provision of this Agreement, or any application thereof to any circumstances, is invalid, in whole or in part, such provision
or application shall to that extent be severable and shall not affect other provisions or applications of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. <U>Governing
Law</U>. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with,
the laws of the State of Delaware, without regard to its conflict of laws rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. <U>Dispute
Resolution</U>. In the event of any dispute arising under or pursuant to this Agreement, the parties agree to attempt to resolve the
dispute in a commercially reasonable fashion before instituting any litigation (with the exception of emergency injunctive relief). If
the parties are unable to resolve the dispute within thirty (30) days, then the parties agree to mediate the dispute with a mutually
agreed upon mediator in New York, NY. If the parties cannot agree upon a mediator within ten (10) days after either party shall first
request commencement of mediation, each party will select a mediator within five (5) days thereof, and those mediators shall select the
mediator to be used. The mediation shall be scheduled within thirty (30) days following the selection of the mediator. The parties further
agree that any applicable statute of limitations will be tolled for the period of time from the date mediation is requested until 14
days following the mediation. If the mediation does not resolve the dispute, then the parties irrevocably and unconditionally (i) agree
that any action or proceeding arising out of or in connection with this Agreement shall be brought in the Chancery Court of the State
of Delaware (the &ldquo;<U>Delaware Court</U>&rdquo;), and not in any other state or federal court in the United States of America or
any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action
or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action
or proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding
brought in the Delaware Court has been brought in an improper or inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16. <U>Legal
Fees</U>. The parties hereto agree that the non-prevailing party in any dispute, claim, action, or proceeding between the parties hereto
arising out of or relating to the terms and conditions of this Agreement or any provision thereof (a &ldquo;<U>Dispute</U>&rdquo;), shall
reimburse the prevailing party for reasonable attorney&rsquo;s fees and expenses incurred by the prevailing party in connection with
such Dispute; provided, however, that the Director shall only be required to reimburse the Company for its fees and expenses incurred
in connection with a Dispute if the Director&rsquo;s position in such Dispute was found by the court, arbitrator, or other person or
entity presiding over such Dispute to be frivolous or advanced not in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17. <U>Mutual
Non-Disparagement</U>. The parties mutually agree to forbear from making, causing to be made, publishing, ratifying, or endorsing any
and all disparaging remarks, derogatory statements or comments made to any party with respect to either of them. Nothing herein shall
prohibit Director from enforcing her rights under the restricted stock award agreement and the stock option award agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18. <U>Modifications</U>.
Neither this Agreement nor any provision hereof may be modified, altered, amended, or waived except by an instrument in writing duly
signed by the party to be charged.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19. <U>Tense
and Headings</U>. Whenever any words used herein are in the singular form, they shall be construed as though they were also used in the
plural form in all cases where they would so apply. The headings contained herein are solely for the purposes of reference, are not part
of this Agreement and shall not in any way affect the meaning or interpretation of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20. <U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together
shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[-Signature
Page Follows-]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Director Agreement to be executed by authority of its Board, and the Director has hereunto
set her hand, on the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">LIFEMD, INC.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><I>/s/ Justin Schreiber</I></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Justin Schreiber</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">DIRECTOR</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><I>/s/ William Febbo</I></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>William Febbo, an individual</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page To Director Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIFEMD,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR
AND OFFICER INDEMNIFICATION AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Director and Officer Indemnification Agreement, dated as of June 20, 2023 (the <B><I>&ldquo;Agreement&rdquo;</I></B>), is made by and
between LifeMD, Inc., a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>), and William Febbo (the <B><I>&ldquo;Indemnitee&rdquo;</I></B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. The
Delaware General Corporation Law provides that the business and affairs of a corporation shall be managed by or under the direction of
its board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B. By
virtue of the managerial prerogatives vested in the directors and officers of a Delaware corporation, directors, and officers act as
fiduciaries of the corporation and its stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C. It
is critically important to the Company and its stockholders that the Company be able to attract and retain the most capable persons reasonably
available to serve as directors and officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D. In
recognition of the need for corporations to be able to induce capable and responsible persons to accept positions in corporate management,
Delaware law authorizes (and in some instances requires) corporations to indemnify their directors and officers, and further authorizes
corporations to purchase and maintain insurance for the benefit of their directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E. Courts
have recognized that indemnification by a corporation serves the dual policies of (1) allowing corporate officials to resist unjustified
lawsuits, secure in the knowledge that, if vindicated, the corporation will bear the expense of litigation, and (2) encouraging capable
women and men to serve as corporate directors and officers, secure in the knowledge that the corporation will absorb the costs of defending
their honesty and integrity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F. The
number of lawsuits challenging the judgment and actions of directors and officers of corporations, the costs of defending those lawsuits,
and the threat to personal assets have all materially increased over the past several years, chilling the willingness of capable women
and men to undertake the responsibilities imposed on corporate directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G. Recent
federal legislation and rules adopted by the Securities and Exchange Commission and the national securities exchanges have exposed such
directors and officers to new and substantially broadened civil liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H. Under
Delaware law, a director&rsquo;s or officer&rsquo;s right to be reimbursed for the costs of defense of criminal actions, whether such
claims are asserted under state or federal law, does not depend upon the merits of the claims asserted against the director or officer
and is separate and distinct from any right to indemnification the director may be able to establish.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I. Indemnitee
is, or will be, a director of the Company and her or her willingness to serve in such capacity is predicated, in substantial part, upon
the Company&rsquo;s willingness to indemnify him or her in accordance with the principles reflected above, to the fullest extent permitted
by the laws of the State of Delaware, and upon the other undertakings set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.
In recognition of the need to provide Indemnitee with substantial protection against personal liability, in order to procure Indemnitee&rsquo;s
service as a director of the Company and to enhance Indemnitee&rsquo;s ability to serve the Company in an effective manner, and in order
to provide such protection pursuant to express contract rights (intended to be enforceable irrespective of, among other things, any amendment
to the Company&rsquo;s certificate of incorporation or bylaws (collectively, the <B><I>&ldquo;Constituent Documents&rdquo;</I></B>),
any change in the composition of the Company&rsquo;s Board of Directors (the <B><I>&ldquo;Board&rdquo;</I></B>), or any change-in-control
or business combination transaction relating to the Company), the Company wishes to provide in this Agreement for the indemnification
and advancement of Expenses (as defined herein) to Indemnitee on the terms, and subject to the conditions, set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">K. In
light of the considerations referred to in the preceding recitals, it is the Company&rsquo;s intention and desire that the provisions
of this Agreement be construed liberally, subject to their express terms, to maximize the protections to be provided to Indemnitee hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AGREEMENT:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, the parties hereto hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Certain
Definitions</U>. In addition to terms defined elsewhere herein, the following terms have the following meanings when used in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) <B><I>&ldquo;Change
in Control&rdquo;</I></B> shall have occurred at such time, if any, as Incumbent Directors cease for any reason to constitute a majority
of the directors. For purposes of this Section 1(a), <B><I>&ldquo;Incumbent Directors&rdquo;</I></B> means the individuals who, as of
the date hereof, are directors of the Company and any individual becoming a director subsequent to the date hereof whose election, nomination
for election by the Company&rsquo;s stockholders, or appointment, was approved by a vote of at least a majority of the then Incumbent
Directors (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee
for director, without objection to such nomination); provided, however, that an individual shall not be an Incumbent Director if such
individual&rsquo;s election or appointment to the Board occurs as a result of an actual or threatened election contest (as described
in Rule 14a-12(c) of the Securities Exchange Act of 1934, as amended) with respect to the election or removal of directors or other actual
or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) <B><I>&ldquo;Claim&rdquo;
</I></B>means (i) any threatened, asserted, pending, or completed claim, demand, action, suit, or proceeding&mdash;whether civil, criminal,
administrative, arbitrative, investigative, or other, and whether made pursuant to federal, state or other law; and (ii) any inquiry
or investigation&mdash;whether made, instituted, or conducted by the Company or any other Person&mdash;including, without limitation,
any federal, state, or other governmental entity that Indemnitee reasonably determines might lead to the institution of any such claim,
demand, action, suit or proceeding. For the avoidance of doubt, the Company intends the indemnity to be provided hereunder for acts or
failure to act prior to, on, or after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <B><I>&ldquo;Controlled
Affiliate&rdquo;</I></B> means any corporation, limited liability company, partnership, joint venture, trust, or other entity or enterprise,
whether or not for profit, that is directly or indirectly controlled by the Company. For purposes of this definition, <B><I>&ldquo;control&rdquo;
</I></B>means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of
an entity or enterprise, whether through the ownership of voting securities, through other voting rights, by contract, or otherwise;
provided that direct or indirect beneficial ownership of capital stock or other interests in an entity or enterprise entitling the holder
to cast 15% or more of the total number of votes generally entitled to be cast in the election of directors (or persons performing comparable
functions) of such entity or enterprise shall be deemed to constitute control for purposes of this definition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) <B><I>&ldquo;Disinterested
Director&rdquo;</I></B> means a director of the Company who is not and was not a party to the Claim in respect of which indemnification
is sought by Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) <B><I>&ldquo;Expenses&rdquo;
</I></B>means reasonable attorneys&rsquo; and experts&rsquo; fees and expenses, and all other costs and expenses paid or payable in connection
with investigating, defending, being a witness in, or participating in (including on appeal), or preparing to investigate, defend, be
a witness in or participate in (including on appeal), any Claim.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f) <B><I>&ldquo;Indemnifiable
Claim&rdquo;</I></B> means any Claim based upon, arising out of or resulting from (i) any actual, alleged or suspected act or failure
to act by Indemnitee in her capacity as a director, officer, employee, or agent of the Company or as a director, officer, employee, member,
manager, trustee, or agent of any other corporation, limited liability company, partnership, joint venture, trust, or other entity or
enterprise, whether or not for profit, as to which Indemnitee is or was serving at the request of the Company, (ii) any actual, alleged
or suspected act or failure to act by Indemnitee in respect of any business, transaction, communication, filing, disclosure or other
activity of the Company or any other entity or enterprise referred to in clause (i) of this sentence, or (iii) Indemnitee&rsquo;s status
as a current or former director, officer, employee, or agent of the Company or as a current or former director, officer, employee, member,
manager, trustee, or agent of the Company or any other entity or enterprise referred to in clause (i) of this sentence or any actual,
alleged, or suspected act or failure to act by Indemnitee in connection with any obligation or restriction imposed upon Indemnitee by
reason of such status. In addition to any service at the actual request of the Company, for purposes of this Agreement, Indemnitee shall
be deemed to be serving or to have served at the request of the Company as a director, officer, employee, member, manager, trustee, or
agent of another entity or enterprise if Indemnitee is or was serving as a director, officer, employee, member, manager, agent, trustee
or other fiduciary of such entity or enterprise and (i) such entity or enterprise is, or at the time of such service was, a Controlled
Affiliate, (ii) such entity or enterprise is or at the time of such service was an employee benefit plan (or related trust) sponsored
or maintained by the Company or a Controlled Affiliate, or (iii) the Company or a Controlled Affiliate (by action of the Board, any committee
thereof or the Company&rsquo;s Chief Executive Officer (&ldquo;CEO&rdquo;) (other than as the CEO himself)) caused or authorized Indemnitee
to be nominated, elected, appointed, designated, employed, engaged, or selected to serve in such capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g) <B><I>&ldquo;Indemnifiable
Losses&rdquo;</I></B> means any and all Losses relating to, arising out of or resulting from any Indemnifiable Claim; provided, however,
that Indemnifiable Losses shall not include Expenses incurred by Indemnitee in respect of any Indemnifiable Claim (or any matter or issue
therein) as to which Indemnitee shall have been adjudged liable to the Company (where such adjudication must be final and non-appealable),
unless and only to the extent that the court in which such Indemnifiable Claim was brought shall have determined upon application that,
despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled
to indemnification for such Expenses as the court shall deem proper (<I>i.e.</I>, there was no bad faith, gross negligence, and/or willful
misconduct by the Director).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h) <B><I>&ldquo;Independent
Counsel&rdquo;</I></B> means a nationally recognized law firm, or a member of a nationally recognized law firm, that is experienced in
matters of Delaware corporate law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company
(or any subsidiary) or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee
under this Agreement, or of other indemnitees under similar indemnification agreements) or (ii) any other named (or, as to a threatened
matter, reasonably likely to be named) party to the Indemnifiable Claim giving rise to a claim for indemnification hereunder. Notwithstanding
the foregoing, the term &ldquo;Independent Counsel&rdquo; shall not include any person who, under the applicable standards of professional
conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine
Indemnitee&rsquo;s rights under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) <B><I>&ldquo;Losses&rdquo;
</I></B>means any and all Expenses, damages, losses, liabilities, judgments, fines, penalties (whether civil, criminal, or other), and
amounts paid or payable in settlement, including, without limitation, all interest, assessments, and other charges paid or payable in
connection with or in respect of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j) <B><I>&ldquo;Person&rdquo;
</I></B>means any individual, entity, or group, within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of
1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k) <B><I>&ldquo;Standard
of Conduct&rdquo;</I></B> means the standard for conduct by Indemnitee that is a condition precedent to indemnification of Indemnitee
hereunder against Indemnifiable Losses relating to, arising out of, or resulting from an Indemnifiable Claim. The Standard of Conduct
is (i) good faith and a reasonable belief by Indemnitee that her action was in or not opposed to the best interests of the Company and,
with respect to any criminal action or proceeding, that Indemnitee had no reasonable cause to believe that her conduct was unlawful,
or (ii) any other applicable standard of conduct that may hereafter be substituted under the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Indemnification
Obligation</U>. Subject only to Section 7 and to the proviso in this Section, the Company shall indemnify, defend and hold harmless Indemnitee,
to the fullest extent permitted by the laws of the State of Delaware in effect on the date hereof or as such laws may from time to time
hereafter be amended to increase the scope of such permitted indemnification, against any and all Indemnifiable Claims and Indemnifiable
Losses; provided, however, that, except as provided in Section 5, Indemnitee shall not be entitled to indemnification pursuant to this
Agreement in connection with (i) any Claim initiated by Indemnitee against the Company or any director or officer of the Company unless
the Company has joined in or consented to the initiation of such Claim or the Claim relates to or arises from the enforcement or prosecution
of a right to indemnification under this Agreement, or (ii) the purchase and sale by Indemnitee of securities in violation of Section
16(b) of the Securities Exchange Act of 1934, as amended. Nothing herein is intended to limit the scope of permitted indemnification
to Indemnitee under the laws of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <U>Advancement
of Expenses</U>. Indemnitee shall have the right to advancement by the Company, prior to the final disposition of any Indemnifiable Claim,
of any and all actual and reasonable Expenses relating to, arising out of, or resulting from any Indemnifiable Claim paid or incurred
by Indemnitee. Without limiting the generality or effect of any other provision hereof, Indemnitee&rsquo;s right to such advancement
is not subject to the satisfaction of any Standard of Conduct. Without limiting the generality or effect of the foregoing, within ten
business days after any request by Indemnitee that is accompanied by supporting documentation for specific reasonable Expenses to be
reimbursed or advanced, the Company shall, in accordance with such request (but without duplication), (a) pay such Expenses on behalf
of Indemnitee, (b) advance to Indemnitee funds in an amount sufficient to pay such Expenses, or (c) reimburse Indemnitee for such Expenses;
provided that Indemnitee shall repay, without interest, any amounts actually advanced to Indemnitee that, at the final disposition of
the Indemnifiable Claim to which the advance related, were in excess of amounts paid or payable by Indemnitee in respect of Expenses
relating to, arising out of or resulting from such Indemnifiable Claim. In connection with any such payment, advancement, or reimbursement,
at the request of the Company, Indemnitee shall execute and deliver to the Company an undertaking, which need not be secured and shall
be accepted without reference to Indemnitee&rsquo;s ability to repay the Expenses, by or on behalf of the Indemnitee, to repay any amounts
paid, advanced, or reimbursed by the Company in respect of Expenses relating to, arising out of, or resulting from any Indemnifiable
Claim in respect of which it shall have been determined, following the final disposition of such Indemnifiable Claim and in accordance
with <U>Section 7</U>, that Indemnitee is not entitled to indemnification hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <U>Indemnification
for Additional Expenses</U>. Without limiting the generality or effect of the foregoing, the Company shall indemnify and hold harmless
Indemnitee against and, if requested by Indemnitee, shall reimburse Indemnitee for, or advance to Indemnitee, within ten business days
of such request accompanied by supporting documentation for specific Expenses to be reimbursed or advanced, any and all actual and reasonable
Expenses paid or incurred by Indemnitee in connection with any Claim made, instituted, or conducted by Indemnitee for (a) indemnification
or reimbursement or advance payment of Expenses by the Company under any provision of this Agreement, or under any other agreement or
provision of the Constituent Documents now or hereafter in effect relating to Indemnifiable Claims, and/or (b) recovery under any directors&rsquo;
and officers&rsquo; liability insurance policies maintained by the Company; provided, however, if it is ultimately determined that the
Indemnitee is not entitled to such indemnification, reimbursement, advance or insurance recovery, as the case may be, then the Indemnitee
shall be obligated to repay any such Expenses to the Company; provided further, that, regardless in each case of whether Indemnitee ultimately
is determined to be entitled to such indemnification, reimbursement, advance, or insurance recovery, as the case may be, Indemnitee shall
return, without interest, any such advance of Expenses (or portion thereof) which remains unspent at the final disposition of the Claim
to which the advance related.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <U>Partial
Indemnity</U>. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion
of any Indemnifiable Loss but not for the entire amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion
thereof to which Indemnitee is entitled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <U>Procedure
for Notification</U>. To obtain indemnification under this Agreement in respect of an Indemnifiable Claim or Indemnifiable Loss, Indemnitee
shall submit to the Company a written request therefore, including a brief description (based upon information then available to Indemnitee)
of such Indemnifiable Claim or Indemnifiable Loss. If, at the time of the receipt of such request, the Company has directors&rsquo; and
officers&rsquo; liability insurance in effect under which coverage for such Indemnifiable Claim or Indemnifiable Loss is potentially
available, the Company shall give prompt written notice of such Indemnifiable Claim or Indemnifiable Loss to the applicable insurers
in accordance with the procedures set forth in the applicable policies. The Company shall thereafter take all necessary or desirable
action to cause such insurers to pay, on behalf of the Indemnitee, all Indemnifiable Claims and Indemnifiable Losses in accordance with
the terms of such policies. The Company shall provide to Indemnitee a copy of such notice delivered to the applicable insurers, substantially
concurrently with the delivery thereof by the Company. The failure by Indemnitee to timely notify the Company of any Indemnifiable Claim
or Indemnifiable Loss shall not relieve the Company from any liability hereunder unless, and only to the extent that, the Company did
not otherwise learn of such Indemnifiable Claim or Indemnifiable Loss and to the extent that such failure results in forfeiture by the
Company of substantial defenses, rights, or insurance coverage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <U>Determination
of Right to Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) To
the extent that Indemnitee shall have been successful on the merits or otherwise in defense of any Indemnifiable Claim or any portion
thereof or in defense of any issue or matter therein, including, without limitation, dismissal without prejudice, Indemnitee shall be
indemnified against all Indemnifiable Losses relating to, arising out of or resulting from such Indemnifiable Claim in accordance with
Section 2 and no Standard of Conduct Determination (as defined in Section 7(b)) shall be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) To
the extent that the provisions of Section 7(a) are inapplicable to an Indemnifiable Claim that shall have been finally disposed of, any
determination required to be made under the laws of the State of Delaware as to whether Indemnitee has satisfied the applicable Standard
of Conduct (a <B><I>&ldquo;Standard of Conduct Determination&rdquo;</I></B>) shall be made as follows: (i) if a Change in Control shall
not have occurred, or if a Change in Control shall have occurred but Indemnitee shall have requested that the Standard of Conduct Determination
be made pursuant to this clause (i), (A) by a majority vote of the Disinterested Directors, even if less than a quorum of the Board,
(B) if such Disinterested Directors so direct, by a majority vote of a committee of Disinterested Directors designated by a majority
vote of all Disinterested Directors, or (C) if there are no such Disinterested Directors, or if a majority of the Disinterested Directors
so direct, by Independent Counsel in a written opinion addressed to the Board, a copy of which shall be delivered to Indemnitee; and
(ii) if a Change in Control shall have occurred and Indemnitee shall not have requested that the Standard of Conduct Determination be
made pursuant to clause (i) above, by Independent Counsel in a written opinion addressed to the Board, a copy of which shall be delivered
to Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) If
(i) Indemnitee shall be entitled to indemnification hereunder against any Indemnifiable Losses pursuant to Section 7(a), (ii) no determination
of whether Indemnitee has satisfied any applicable standard of conduct under Delaware law is a legally required condition precedent to
indemnification of Indemnitee hereunder against any Indemnifiable Losses, or (iii) Indemnitee has been determined or deemed pursuant
to Section 7(b) to have satisfied the applicable Standard of Conduct, then the Company shall pay to Indemnitee, within ten business days
after the later of (x) the notification date in respect of the Indemnifiable Claim or portion thereof to which such Indemnifiable Losses
are related, out of which such Indemnifiable Losses arose or from which such Indemnifiable Losses resulted, and (y) the earliest date
on which the applicable criterion specified in clause (i), (ii) or (iii) above shall have been satisfied, an amount equal to the amount
of such Indemnifiable Losses. Nothing herein is intended to mean or imply that the Company is intending to use the Delaware General Corporations
Law to dispense with a requirement that Indemnitee meet the applicable Standard of Conduct where it is otherwise required by such statute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) If
a Standard of Conduct Determination is required to be, but has not been, made by Independent Counsel pursuant to Section 7(b)(i), the
Independent Counsel shall be selected by the Board or a committee of the Board, and the Company shall give written notice to Indemnitee
advising him or her of the identity of the Independent Counsel so selected. If a Standard of Conduct Determination is required to be,
or to have been, made by Independent Counsel pursuant to Section 7(b)(ii), the Independent Counsel shall be selected by Indemnitee, and
Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either case,
Indemnitee or the Company, as applicable, may, within ten business days after receiving written notice of selection from the other, deliver
to the other a written objection to such selection<I>; </I>provided, however, that such objection may be asserted only on the ground
that the Independent Counsel so selected does not satisfy the criteria set forth in the definition of &ldquo;Independent Counsel&rdquo;
in Section 1(h), and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely
objection, the Person so selected shall act as Independent Counsel. If such written objection is properly and timely made and substantiated,
(i) the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court
has determined that such objection is without merit and (ii) the non-objecting party may, at its option, select an alternative Independent
Counsel and give written notice to the other party advising such other party of the identity of the alternative Independent Counsel so
selected, in which case the provisions of the two immediately preceding sentences and clause (i) of this sentence shall apply to such
subsequent selection and notice. If applicable, the provisions of clause (ii) of the immediately preceding sentence shall apply to successive
alternative selections. If no Independent Counsel that is permitted under the foregoing provisions of this Section 7(d) to make the Standard
of Conduct Determination shall have been selected within 30 calendar days after the Company gives its initial notice pursuant to the
first sentence of this Section 7(d) or Indemnitee gives its initial notice pursuant to the second sentence of this Section 7(d), as the
case may be, either the Company or Indemnitee may petition the courts of the State of Delaware for resolution of any objection which
shall have been made by the Company or Indemnitee to the other&rsquo;s selection of Independent Counsel and/or for the appointment as
Independent Counsel of a person or firm selected by such court or by such other person as such Court shall designate, and the person
or firm with respect to whom all objections are so resolved or the person or firm so appointed will act as Independent Counsel. In all
events, the Company shall pay all of the actual and reasonable fees and expenses of the Independent Counsel incurred in connection with
the Independent Counsel&rsquo;s determination pursuant to Section 7(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8. <U>Cooperation</U>.
Indemnitee shall cooperate with reasonable requests of the Company in connection with any Indemnifiable Claim and any individual or firm
making such Standard of Conduct Determination, including providing to such Person documentation or information which is not privileged
or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to defend the Indemnifiable
Claim or make any Standard of Conduct Determination without incurring any unreimbursed cost in connection therewith. The Company shall
indemnify and hold harmless Indemnitee against and, if requested by Indemnitee, shall reimburse Indemnitee for, or advance to Indemnitee,
within ten business days of such request accompanied by supporting documentation for specific costs and expenses to be reimbursed or
advanced, any and all costs and expenses (including reasonable attorneys&rsquo; and experts&rsquo; fees and expenses) actually and reasonably
incurred by Indemnitee in so cooperating with the Person defending the Indemnifiable Claim or making such Standard of Conduct Determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9. <U>Presumption
of Entitlement</U>. Notwithstanding any other provision hereof, in making any Standard of Conduct Determination, the Person making such
determination shall presume that Indemnitee has satisfied the applicable Standard of Conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. <U>No
Other Presumption</U>. For purposes of this Agreement, the termination of any Claim by judgment, order, settlement (whether with or without
court approval) or conviction, or upon a plea of nolo contendere or its equivalent, will not create a presumption that Indemnitee did
not meet any applicable Standard of Conduct or that indemnification hereunder is otherwise not permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. <U>Non-Exclusivity</U>.
The rights of Indemnitee hereunder will be in addition to any other rights Indemnitee may have under the Constituent Documents, or the
substantive laws of the State of Delaware, any other contract or otherwise (collectively, <B><I>&ldquo;Other Indemnity Provisions&rdquo;</I></B>);
provided, however, that (a) to the extent that Indemnitee otherwise would have any greater right to indemnification under any Other Indemnity
Provision, Indemnitee will without further action be deemed to have such greater right hereunder, and (b) to the extent that any change
is made to any Other Indemnity Provision which permits any greater right to indemnification than that provided under this Agreement as
of the date hereof, Indemnitee will be deemed to have such greater right hereunder. The Company may not, without the consent of Indemnitee,
adopt any amendment to any of the Constituent Documents the effect of which would be to deny, diminish, or encumber Indemnitee&rsquo;s
right to indemnification under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12. <U>Liability
Insurance and Funding</U>. For the duration of Indemnitee&rsquo;s service as a director of the Company and for a reasonable period of
time thereafter, which such period shall be determined by the Company in its sole discretion but shall in no event be less than two (2)
years, the Company shall cause to be maintained in effect policies of directors&rsquo; and officers&rsquo; liability insurance providing
coverage for directors and/or officers of the Company, that is substantially comparable in scope and amount to that provided by the Company&rsquo;s
current policies of directors&rsquo; and officers&rsquo; liability insurance. Upon reasonable request, the Company shall provide Indemnitee
or her or her counsel with a copy of all directors&rsquo; and officers&rsquo; liability insurance applications, binders, policies, declarations,
endorsements, and other related materials. In all policies of directors&rsquo; and officers&rsquo; liability insurance obtained by the
Company, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights and benefits, subject to the
same limitations, as are accorded to the Company&rsquo;s directors and officers most favorably insured by such policy. Notwithstanding
the foregoing, the Company may, but shall not be required to, create a trust fund, grant a security interest, or use other means, including,
without limitation, a letter of credit, to ensure the payment of such amounts as may be necessary to satisfy its obligations to indemnify
and advance expenses pursuant to this Agreement. The Company understands and acknowledges that the Director may resign from all positions
with the Company if it fails to timely implement, or to thereafter maintain in place, such increased coverages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. <U>Subrogation</U>.
In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the related rights
of recovery of Indemnitee against other Persons (other than Indemnitee&rsquo;s successors), including any entity or enterprise referred
to in clause (i) of the definition of &ldquo;Indemnifiable Claim&rdquo; in Section 1(f). Indemnitee shall execute all papers reasonably
required to evidence such rights (all of Indemnitee&rsquo;s reasonable Expenses, including reasonable attorneys&rsquo; fees and charges,
related thereto to be reimbursed by or, at the option of Indemnitee, advanced by the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14. <U>No
Duplication of Payments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Company shall not be liable under this Agreement to make any payment to Indemnitee in respect of any Indemnifiable Losses to the extent
Indemnitee has otherwise already actually received payment (net of Expenses incurred in connection therewith) under any insurance policy,
the Constituent Documents and Other Indemnity Provisions or otherwise (including from any entity or enterprise referred to in clause
(i) of the definition of &ldquo;Indemnifiable Claim&rdquo; in Section 1(f)) in respect of such Indemnifiable Losses otherwise indemnifiable
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Notwithstanding
anything to the contrary contained in Section 14(a) above, the Company hereby acknowledges that Indemnitee may have certain rights to
indemnification, advancement of expenses, and/or insurance provided by one or more venture capital funds, the general partners, managing
members, or other control persons and/or any affiliated management companies of such venture capital funds, and certain of its or their
affiliates (collectively, the &ldquo;<B><I>Fund Indemnitors</I></B>&rdquo;). The Company hereby agrees that in connection with any Indemnifiable
Claim, (i) it is the indemnitor of first resort (<I>i.e.</I>, its obligations to Indemnitee are primary and any obligation of the Fund
Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary),
(ii) it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all
Expenses, judgments, penalties, fines, and amounts paid in settlement to the extent legally permitted and as required by the terms of
this Agreement and the Company&rsquo;s Constituent Documents (or any other agreement between the Company and Indemnitee), without regard
to any rights Indemnitee may have against the Fund Indemnitors, and, (iii) it irrevocably waives, relinquishes, and releases the Fund
Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect
thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any
claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have
a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee
against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of
this Section 14(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. <U>Defense
of Claims</U>. Subject to the provisions of applicable policies of directors&rsquo; and officers&rsquo; liability insurance, if any,
the Company shall be entitled to participate in the defense of any Indemnifiable Claim or to assume or lead the defense thereof with
counsel reasonably satisfactory to the Indemnitee; provided that if Indemnitee determines, after consultation with counsel selected by
Indemnitee, that (a) the use of counsel chosen by the Company to represent Indemnitee would present such counsel with an actual or potential
conflict, (b) the named parties in any such Indemnifiable Claim (including any impleaded parties) include both the Company and Indemnitee,
and Indemnitee shall conclude that there may be one or more legal defenses available to him or her that are different from or in addition
to those available to the Company, (c) any such representation by such counsel would be precluded under the applicable standards of professional
conduct then prevailing, or (d) Indemnitee has interests in the claim or underlying subject matter that are different from or in addition
to those of other Persons against whom the Claim has been made or might reasonably be expected to be made, then Indemnitee shall be entitled
to retain separate counsel (but not more than one law firm plus, if applicable, local counsel in respect of any particular Indemnifiable
Claim for all indemnitees in Indemnitee&rsquo;s circumstances) at the Company&rsquo;s expense. The Company shall not be liable to Indemnitee
under this Agreement for any amounts paid in settlement of any threatened or pending Indemnifiable Claim effected without the Company&rsquo;s
prior written consent. The Company shall not, without the prior written consent of the Indemnitee, effect any settlement of any threatened
or pending Indemnifiable Claim to which the Indemnitee is or could have been a party unless such settlement solely involves the payment
of money and includes a complete and unconditional release of the Indemnitee from all liability on any claims that are the subject matter
of such Indemnifiable Claim. Neither the Company nor Indemnitee shall unreasonably withhold its consent to any proposed settlement; provided
that Indemnitee may withhold consent to any settlement that does not provide a complete and unconditional release of Indemnitee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16. <U>Mutual
Acknowledgment</U>. Both the Company and the Indemnitee acknowledge that in certain instances, Federal law or applicable public policy
may prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. Indemnitee understands and acknowledges
that the Company may be required in the future to undertake to the Securities and Exchange Commission to submit the question of indemnification
to a court in certain circumstances for a determination of the Company&rsquo;s right under public policy to indemnify Indemnitee and,
in that event, the Indemnitee&rsquo;s rights and the Company&rsquo;s obligations hereunder shall be subject to that determination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17. <U>Successors
and Binding Agreement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) This
Agreement shall be binding upon and inure to the benefit of the Company and any successor to the Company, including, without limitation,
any Person acquiring directly or indirectly all or substantially all of the business or assets of the Company whether by purchase, merger,
consolidation, reorganization, or otherwise (and such successor will thereafter be deemed the &ldquo;Company&rdquo; for purposes of this
Agreement), but shall not otherwise be assignable or delegable by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) This
Agreement shall inure to the benefit of and be enforceable by the Indemnitee&rsquo;s personal or legal representatives, executors, administrators,
heirs, distributees, legatees, and other successors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) This
Agreement is personal in nature and neither of the parties hereto shall, without the consent of the other, assign or delegate this Agreement
or any rights or obligations hereunder except as expressly provided in Sections 17(a) and 17(b). Without limiting the generality or effect
of the foregoing, Indemnitee&rsquo;s right to receive payments hereunder shall not be assignable, whether by pledge, creation of a security
interest, or otherwise, other than by a transfer by the Indemnitee&rsquo;s will or by the laws of descent and distribution, and, in the
event of any attempted assignment or transfer contrary to this Section 17(c), the Company shall have no liability to pay any amount so
attempted to be assigned or transferred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18. <U>Notices</U>.
For all purposes of this Agreement, all communications, including without limitation notices, consents, requests, or approvals, required
or permitted to be given hereunder must be in writing and shall be deemed to have been duly given when hand delivered, email with read
receipt (legal@lifemd.com), or dispatched by electronic facsimile transmission (with receipt thereof orally confirmed), or one business
day after having been sent for next-day delivery by a nationally recognized overnight courier service, addressed to the Company (to the
attention of the General Counsel of the Company) and to Indemnitee at the applicable address shown on the signature page hereto, or to
such other address as any party hereto may have furnished to the other in writing and in accordance herewith, except that notices of
changes of address will be effective only upon receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19. <U>Governing
Law</U>. The validity, interpretation, construction, and performance of this Agreement shall be governed by and construed in accordance
with the substantive laws of the State of Delaware, without giving effect to the principles of conflict of laws of such State. The Company
and Indemnitee each hereby irrevocably consent to the jurisdiction of the courts of the State of Delaware for all purposes in connection
with any action or proceeding which arises out of or relates to this Agreement, waive all procedural objections to suit in that jurisdiction,
including, without limitation, objections as to venue or inconvenience, agree that service in any such action may be made by notice given
in accordance with Section 18 and also agree that any action instituted under this Agreement shall be brought only in the Chancery Court
of the State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20. <U>Dispute
Resolution</U>. In the event of any dispute arising under or pursuant to this Agreement, the parties agree to attempt to resolve the
dispute in a commercially reasonable fashion before instituting any litigation (with the exception of emergency injunctive relief). If
the parties are unable to resolve the dispute within thirty (30) days, then the parties agree to mediate the dispute with a mutually
agreed upon mediator in New York, NY. If the parties cannot agree upon a mediator within ten (10) days after either party shall first
request commencement of mediation, each party will select a mediator within five (5) days thereof, and those mediators shall select the
mediator to be used. The mediation shall be scheduled within thirty (30) days following the selection of the mediator. The parties further
agree that any applicable statute of limitations will be tolled for the period of time from the date mediation is requested until 14
days following the mediation. If the mediation does not resolve the dispute, then the parties irrevocably and unconditionally (i) agree
that any action or proceeding arising out of or in connection with this Agreement shall be brought in the Chancery Court of the State
of Delaware (the &ldquo;<U>Delaware Court</U>&rdquo;), and not in any other state or federal court in the United States of America or
any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action
or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action
or proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding
brought in the Delaware Court has been brought in an improper or inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20. <U>Validity</U>.
If any provision of this Agreement or the application of any provision hereof to any Person or circumstance is held invalid, unenforceable,
or otherwise illegal, the remainder of this Agreement and the application of such provision to any other Person or circumstance shall
not be affected, and the provision so held to be invalid, unenforceable, or otherwise illegal shall be reformed to the extent, and only
to the extent, necessary to make it enforceable, valid, or legal. In the event that any court or other adjudicative body shall decline
to reform any provision of this Agreement held to be invalid, unenforceable, or otherwise illegal as contemplated by the immediately
preceding sentence, the parties hereto shall take all such action as may be necessary or appropriate to replace the provision so held
to be invalid, unenforceable, or otherwise illegal with one or more alternative provisions that effectuate the purpose and intent of
the original provisions of this Agreement as fully as possible without being invalid, unenforceable, or otherwise illegal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21. <U>Miscellaneous</U>.
No provision of this Agreement may be waived, modified, or discharged unless such waiver, modification or discharge is agreed to in writing
signed by Indemnitee and the Company. No waiver by either party hereto at any time of any breach by the other party hereto or compliance
with any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar
provisions or conditions at the same or at any prior or subsequent time. No agreements or representations, oral or otherwise, expressed
or implied with respect to the subject matter hereof have been made by either party hereto that is not set forth expressly in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22. <U>Certain
Interpretive Matters</U>. Unless the context of this Agreement otherwise requires, (1) &ldquo;it&rdquo; or &ldquo;its&rdquo; or words
of any gender include each other gender, (2) words using the singular or plural number also include the plural or singular number, respectively,
(3) the terms &ldquo;hereof,&rdquo; &ldquo;herein,&rdquo; &ldquo;hereby&rdquo; and derivative or similar words refer to this entire Agreement,
(4) the terms &ldquo;Article,&rdquo; &ldquo;Section,&rdquo; &ldquo;Annex&rdquo; or &ldquo;Exhibit&rdquo; refer to the specified Article,
Section, Annex, or Exhibit of or to this Agreement, (5) the terms &ldquo;include,&rdquo; &ldquo;includes&rdquo; and &ldquo;including&rdquo;
will be deemed to be followed by the words &ldquo;without limitation&rdquo; (whether or not so expressed), and (6) the word &ldquo;or&rdquo;
is disjunctive but not exclusive. Whenever this Agreement refers to a number of days, such number will refer to calendar days unless
business days are specified and whenever action must be taken (including the giving of notice or the delivery of documents) under this
Agreement during a certain period of time or by a particular date that ends or occurs on a non-business day, then such period or date
will be extended until the immediately following business day. As used herein, <B><I>&ldquo;business day&rdquo;</I></B> means any day
other than Saturday, Sunday, or a United States federal holiday.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23. <U>Entire
Agreement</U>. This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written and
oral, between the parties hereto with respect to the subject matter of this Agreement. Any prior agreements or understandings between
the parties hereto with respect to indemnification are hereby terminated and of no further force or effect. This Agreement is not the
exclusive means of securing indemnification rights of Indemnitee and is in addition to any rights Indemnitee may have under any Constituent
Documents or Delaware Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24. <U>Counterparts</U>.
This Agreement may be executed in one or more counterparts, each of which will be deemed to be an original but all of which together
shall constitute one and the same agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25. <U>Duration
of Agreement</U>. This Agreement shall continue until and terminate upon the later of: (a) six years after the date that the Indemnitee
shall have ceased to serve as a director, officer, employee, agent, or fiduciary of the Company or of any other corporation, partnership,
joint venture, trust, employee benefit plan, or other enterprise which the Indemnitee served at the request of the Company; (b) the expiration
of the applicable statutes of limitations pertaining to any and all potential proceedings covered by the indemnification provided for
herein; or (c) the final termination of all pending proceedings in respect of which the Indemnitee is granted rights of indemnification
or advancement of Expenses hereunder and of any proceeding commenced by the Indemnitee pursuant to this Agreement relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[-Signature
Page Follows-]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, Indemnitee has executed, and the Company has caused its duly authorized representative to execute this Agreement as
of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">LIFEMD, INC.</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 47%"><I>/s/ Justin Schreiber</I></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Justin Schreiber</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold">INDEMNITEE:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><I>/s/ William Febbo</I></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>William Febbo, an individual</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page To Director And Officer Indemnification Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIFEMD,
INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESTRICTED
STOCK AWARD AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
RESTRICTED STOCK AWARD (this &ldquo;<B>Agreement</B>&rdquo;) is granted as of June 20, 2023 (the &ldquo;<B>Grant Date</B>&rdquo;), and
reflected in this RESTRICTED STOCK AWARD AGREEMENT (the &ldquo;<B>Agreement</B>&rdquo;) between LifeMD, Inc. (the &ldquo;<B>Company</B>&rdquo;),
and William Febbo (the &ldquo;<B>Director</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company desires to grant the Director, shares of the Company&rsquo;s Common Stock, $0.01 par value (&ldquo;<B>Shares</B>&rdquo;),
subject to certain restrictions as set forth in this Agreement (this &ldquo;<B>Restricted Stock Award</B>&rdquo;), pursuant to the LifeMD,
Inc. 2020 Equity Incentive Plan (the &ldquo;<B>Plan</B>&rdquo;) and any Amendments thereto (capitalized terms not otherwise defined herein
shall have the same meanings as in the Plan);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS<B>,
</B>the Board of Directors (the &ldquo;<B>Board</B>&rdquo;) has determined that it would be to the advantage and best interest of the
Company and its stockholders to grant the Shares herein to the Director; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW
THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Grant
of Restricted Shares</U>. Subject to the terms and conditions of the Plan and the additional terms and conditions set forth in this Agreement,
the Company hereby grants to the Director a restricted Shares award of Seventy Five Thousand (75,000) Shares (the &ldquo;<B>Restricted
Shares</B>&rdquo;). The Restricted Shares shall vest in accordance with Section 2 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Vesting</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Thirty-Seven
Thousand Five Hundred (37,500) Restricted Shares shall vest upon the execution of the Director Agreement dated June 20, 2023 between
the Company and the Director, and Thirty-Seven Thousand Five Hundred (37,500) Restricted Shares shall vest on the two-year anniversary
of the Grant Date, subject to the terms herein and the Director continuing in service on the Board through each applicable vesting date.
Notwithstanding the foregoing, the Restricted Shares shall vest upon the termination of the services provided to the Company by the Director
in her capacity as a director of the Company on account of being removed from such role or otherwise not being asked to stand for re-election
for reasons other than Cause (as that term is defined in a service and/or director agreement of such Director, or if such term or terms
is not defined in a service and/or director agreement or there is not a service agreement, as defined by the Plan). If terminated for
Cause, the Restricted Shares shall vest in a pro rata fashion up until the point of time that served as the basis for termination for
Cause. Similarly, in the case of death or disability, the Restricted Shares shall vest in a pro rata fashion up until the point in time
of death or disability. In lieu of fractional vesting, the number of Restricted Shares shall be rounded up each time until fractional
Restricted Shares are eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Compensation to the extent it is then unvested, shall vest immediately prior to the closing for any Change of Control. As used
herein, &ldquo;Change of Control&rdquo; means: (i) a bona fide transfer or series of related transfers of Shares to any person or Group
in which, or as a result of which, such person or Group obtains the direct or indirect right to elect a majority of the board of directors
of the Company; or (ii) a sale of all or substantially all of the assets of the Company. As used herein, &ldquo;Group&rdquo; means any
group or syndicate that would be considered a &ldquo;person&rdquo; for purposes of Section 13(d) of the Securities Exchange Act of 1934,
as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) However,
notwithstanding any other provisions of this Agreement, at the option of the Board in its sole and absolute discretion, all Restricted
Shares shall be immediately forfeited in the even any of the following events occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) The
Director purchases or sells securities of the Company without written authorization in accordance with the Company&rsquo;s insider trading
policy then in effect, if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) The
Director (A) discloses, publishes or authorizes anyone else to use, disclose or publish, without the prior written consent of the Company,
any proprietary or confidential information of the Company, including, without limitation, any information relating to existing or potential
customers, business methods, financial information, trade or industry practices, sales and marketing strategies, employee information,
vendor lists, business strategies, intellectual property, trade secrets or any other proprietary or confidential information or (B) directly
or indirectly uses any such proprietary or confidential information for the individual benefit of the Director or the benefit of a third
party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) During
the term of the Director&rsquo;s service and for a period of one (1) year thereafter, the Director disrupts or damages, impairs, or interferes
with the business of the Company or its Affiliates by recruiting, soliciting or otherwise inducing any of their respective directors
or employees to enter into employment or other relationship with any other business entity, or terminate or materially diminish their
relationship with the Company or its Affiliates, as applicable. Notably, Director has pre-existing relationships, as well as those created
through the ordinary course of business, from Director&rsquo;s work with the Boston Children&rsquo;s Hospital, Harvard Medical School,
iSelect Fund, Virtue Foundation, and others&mdash;none of which will be deemed a violation of this provision or this Agreement now or
into the future, so long as there is no malicious intent to violate this Agreement through such pre-existing relationships;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) During
the term of the Director&rsquo;s service and for a period of one (1) year thereafter, the Director solicits or directs business of any
person or entity who is (A) a customer of the Company or its Affiliates at any time or (B) solicited to be a &ldquo;prospective customer&rdquo;
of the Company or its Affiliates, in any case either for such Director or for any other person or entity. For purposes of this clause
(v), &ldquo;prospective customer&rdquo; means a person or entity who contacted, or is contacted by, the Company or its Affiliates regarding
the provision of services to or on behalf of such person or entity; provided that the Director has actual knowledge of such prospective
customer. Notably, Director has pre-existing relationships, as well as those created through the ordinary course of business, from Director&rsquo;s
work with the Boston Children&rsquo;s Hospital, Harvard Medical School, iSelect Fund, Virtue Foundation, and others&mdash;none of which
will be deemed a violation of this provision or this Agreement now or into the future, so long as there is no malicious intent to violate
this Agreement through such pre-existing relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The Director fails to reasonably cooperate to effect a smooth transition of the Director&rsquo;s duties and to ensure that the Company
is apprised of the status of all matters the Director is managing or is unavailable for consultation after termination of the Director&rsquo;s
service if such availability is a condition of any agreement to which the Company and the Director are parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi) The
Director fails to assign all of such Director&rsquo;s rights, title and interest in and to any and all ideas, inventions, formulas, source
codes, techniques, processes, concepts, systems, programs, software, computer data bases, trademarks, service marks, brand names, trade
names, compilations, documents, data, notes, designs, drawings, technical data and/or training materials, including improvements thereto
or derivatives therefrom, whether or not patentable or subject to copyright or trademark or trade secret protection, developed and produced
by the Director used or intended for use by or on behalf of the Company or the Company&rsquo;s clients; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 99pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
The Director acts in a disloyal manner to the Company, such as making comments, whether oral or in writing, that tend to disparage or
injure (i) the reputation or business of the Company or its Affiliates, or is likely to result in discredit to, or loss of business,
reputation or goodwill of, the Company or its Affiliates or (ii) its directors, officers, or stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all of the Restricted Shares shall, to the extent it is then unvested, vest immediately prior to the closing for any Change
of Control. As used herein, &ldquo;<B>Change of Control</B>&rdquo; means (i) a <I>bona fide </I>transfer or series of related transfers
of Shares to any person or Group in which, or as a result of which, such person or Group obtains the direct or indirect right to elect
a majority of the board of directors of the Company; or (ii) a sale of all or substantially all of the assets of the Company. As used
herein, &ldquo;<B>Group</B>&rdquo; means any group or syndicate that would be considered a &ldquo;person&rdquo; for purposes of Section
13(d) of the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) For
purposes of this Agreement, &ldquo;<B>Affiliate</B>&rdquo; means with respect to a person or entity, any other person or entity controlled
by, in control of or under common control with such person or entity, and &ldquo;controlled,&rdquo; &ldquo;controlled by,&rdquo; and
&ldquo;under common control with&rdquo; shall mean direct or indirect possession of the power to direct or cause the direction of management
policies (whether through ownership of voting securities, by contract or otherwise, of a person or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <U>Representations
and Warranties; Acknowledgements</U>. In connection with the grant of the Restricted Shares hereunder, the Director represents and warrants
to the Company that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) The
Director is acquiring Restricted Shares for Director&rsquo;s own account, not as a nominee or agent, for investment only and not with
a view towards, or for resale in connection with, the public sale or distribution thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
Director understands that: (a) the Restricted Shares have not been registered under the Securities Act of 1933 as amended (the &ldquo;<B>Securities
Act</B>&rdquo;), or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (A) subsequently
registered thereunder or (B) sold in reliance on an exemption therefrom; and (b) neither the Company nor any other person is under any
obligation to register such securities under the Securities Act or any state securities laws or to comply with the terms and conditions
of any exemption thereunder. In this regard, the Director represents that the Director is familiar with SEC Rule 144, and understands
the resale limitations imposed thereby and by the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
Director is able to bear the economic risk of the Director&rsquo;s investment in the Shares for an indefinite period of time because
the Restricted Shares have not been registered under the Securities Act and, therefore, cannot be sold unless subsequently registered
under the Securities Act or an exemption from such registration is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d) The
Director and the Director&rsquo;s advisers have had an opportunity to ask questions and receive answers concerning the terms and conditions
of the offering of the Shares as the Director and the Director&rsquo;s advisers have requested and have had full and free access and
opportunity to inspect, review, examine, and inquire about such other information concerning the Company and its Affiliates as they have
requested. The Director and the Director&rsquo;s advisers have also been provided with an opportunity to review and ask questions about
the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e) The
Director has had an opportunity to consult with independent legal counsel regarding the Director&rsquo;s rights and obligations under
this Agreement and the Plan, and fully understands the terms and conditions contained herein. The Director is not relying on the Company
or any of its employees, agents, or representatives with respect to the legal, tax, economic, and related considerations of an investment
in the Shares. The Director understands that in the future the Shares may significantly increase or decrease in value, and the Company
has not made any representation to the Director about the potential future value of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. The
Director understands and agrees that the investment in the Company involves a high degree of risk and that no guarantees have been made
or can be made with respect to the future value of the Restricted Shares or the future profitability or success of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <U>Termination
of Relationship</U>. Upon the termination of the Director&rsquo;s service on the Board, all unvested Shares of Restricted Shares shall
be automatically and irrefutably forfeited. If such forfeiture occurs, the Director shall execute and deliver to the Company any and
all further documents (including an Assignment Separate From Certificate) as the Company reasonably requests to further document the
forfeiture. As used in this Agreement, &ldquo;<B>service</B>&rdquo;, &ldquo;<B>termination of service</B>&rdquo; and like terms shall
be construed to include any employment or consulting relationship with the Company or its Affiliates. For purposes of this Agreement,
a change from performing service on the Board to such an employment or consulting relationship or vice versa shall not be treated as
a termination of employment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <U>Redemption</U>.
If any of the events specified in Section 2(b) of this Agreement occur within one (1) year from the last date of the Director&rsquo;s
service (the &ldquo;<B>Termination Date</B>&rdquo;), all Restricted Shares that vested during the one (1) year period ending on the Termination
Date shall be forfeited and forthwith surrendered by the Director to the Company within ten (10) days after the Director receives written
demand from the Company for such Restricted Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <U>Certificates</U>.
Certificates evidencing the Restricted Shares shall be issued by the Company and shall be registered in the Director&rsquo;s name promptly
after the date the shares are vested. No certificates shall be issued for fractional shares, but rather rounded up to the next whole
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Rights as a Stockholder</U>. Neither the Director, the Director&rsquo;s estate, nor the Transferee have any rights as a shareholder
with respect to any Common Stock covered by the Restricted Shares unless and until such Restricted Shares have vested. &ldquo;<B>Transferee</B>&rdquo;
shall mean an individual to whom such Director&rsquo;s vested Restricted Shares are transferred by will or by the laws of descent and
distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Legend on Certificates</U>. The certificates representing the vested Restricted Shares delivered to the Director as contemplated by
Section 5 shall bear such legends, and be subject to such stop transfer orders, as the Company may deem advisable to give notice of restrictions
imposed by this Agreement, the Plan, the rules, regulations, and other requirements of the Securities and Exchange Commission, any stock
exchange upon which such Shares are listed, or any applicable law. The Company may cause a legend or legends to be put on any such certificates
to make appropriate reference to such restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10. <U>Transferability.
</U>To the extent that the Restricted Shares are then unvested, the Director shall not transfer, sell, assign, pledge, hypothecate or
otherwise dispose of the Restricted Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11. <U>Retention
by the Company.</U> Nothing contained in this Agreement or in any other agreement entered into by the Company and the Director contemporaneously
with the execution of this Agreement (i) shall be deemed to obligate the Company or any of its Affiliates to employ or retain the Director
in any capacity whatsoever, or (ii) shall prohibit or restrict the Company or any of its Affiliates from terminating the service, if
any, of the Director at any time or for any reason whatsoever, and the Director hereby acknowledges and agrees that neither the Company
nor any other Person has made any representations or promises whatsoever to the Director concerning the Director&rsquo;s service or continued
service by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12. <U>Sale
of Shares Acquired</U>. If the Director is an officer (as defined by Section 16(b) of the Securities Exchange Act of 1934, as amended
(&ldquo;<B>Section 16(b)</B>&rdquo;), any shares of the Company&rsquo;s Common Stock acquired pursuant to Restricted Stock Awards granted
hereunder cannot be sold by the Director, subject to registration or an exemption from registration such as to Rule 144 promulgated under
the Securities Act, until at least six (6) months elapse from the date of grant of this Restricted Stock Award, except in the case of
death or disability or if the grant was exempt from the short-swing profit provisions of Section 16(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13. <U>Withholding</U>.
The Director acknowledges that the Director is responsible for all liability for applicable tax related to the issuance or vesting of
this Restricted Stock Award. Unless the Director uses a designated broker to sell Shares with an aggregate fair market value sufficient
to cover the amount required to be withheld by the Company, or the Director delivers in cash or certified check the amount required to
be withheld by the Company, the Company will issue the number of Shares owed to the Director under this Restricted Stock Award less a
number of Shares equal to, in the aggregate, the amount of applicable tax related to the delivery of such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Adjustments</U>. The Restricted Shares under this Agreement shall be subject to the terms of the Plan, including but not limited to
Section 3(b) (Changes in Stock) and 3(c) (Sale Events) of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15. <U>Limitation
on Obligations</U>. The Company&rsquo;s obligation with respect to the Restricted Shares granted hereunder is limited solely to the delivery
to the Director of Shares on the date when such Shares are due to be delivered hereunder, and in no way shall the Company become obligated
to pay cash in respect of such obligation. This Restricted Stock Award shall not be secured by any specific assets of the Company, nor
shall any assets of the Company be designated as attributable or allocated to the satisfaction of the Company&rsquo;s obligations under
this Agreement. In addition, the Company shall not be liable to the Director for damages relating to any delays in issuing the share
certificates to him/her (or her designated entities), any loss of the certificates, or any mistakes or errors in the issuance of the
certificates or in the certificates themselves.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<U>Securities Laws</U>. Upon the vesting of any Restricted Shares, the Company may require the Director to make or enter into such written
representations, warranties and agreements as the Committee may reasonably request solely to comply with applicable securities laws or
with this Agreement. The granting of the Restricted Shares hereunder shall be subject to all applicable laws, rules, and regulations
and to such approvals of any governmental agencies as may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17. <U>Arbitration</U>.
Any controversy, dispute or claim arising out of or relating to this Agreement, or its interpretation, application, implementation, breach
or enforcement which the parties hereto are unable to resolve by mutual agreement, shall be settled by submission by either party of
the controversy, claim or dispute to binding arbitration in New York County, New York (unless the parties agree in writing to a different
location), before a single arbitrator in accordance with the rules of the American Arbitration Association then in effect. The decision
and award made by the arbitrator shall be final, binding, and conclusive on all parties hereto for all purposes, and judgment may be
entered thereon in any court having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18. <U>Governing
Law.</U> This Agreement and any dispute, disagreement, or issue of construction or interpretation arising hereunder whether relating
to its execution, its validity, the obligations provided herein or performance, shall be governed or interpreted according to the laws
of the State of Delaware without regard to choice of law considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19. <U>Restricted
Shares Award Subject to Plan</U>. This Restricted Stock Award shall be subject to the terms and provisions of the Plan. In the event
of any conflict between this Agreement and the Plan, the terms of this Agreement shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20. <U>Signature
in Counterparts</U>. This Agreement may be signed in multiple counterparts, each of which shall be deemed an original and all of which
taken together shall be deemed one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21. <U>Copy
of Plan</U>. By execution of this Agreement, the Director acknowledges receipt of a copy of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22. <U>New
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Any
shares of capital stock of the Company or any successor thereto (&ldquo;<B>New Shares</B>&rdquo;) issued by the Company from time to
time (including without limitation in any stock split or stock dividend) with respect to Restricted Shares (&ldquo;<B>Old Shares</B>&rdquo;)
shall also be treated as Restricted Shares for all purposes of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) The
New Shares so issued shall at all times be vested in the same proportion as the Old Shares are vested. For example: (i) if none of the
Old Shares are vested as of the date that the New Shares are issued, then none of the New Shares will be vested when issued, (ii) if,
from time to time, 25% of the Old Shares become vested at any later date, then 25% of the New Shares shall also become vested on that
date; and (ii) if all of the Old Shares are vested on a date, then all of the New Shares shall be vested on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) The
New Shares shall be subject to this Agreement, including without limitation Section 3 thereof, to the same extent as the Old Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B>, the parties hereto have executed this Restricted Stock Award Agreement as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIFEMD,
    INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Justin Schreiber</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
    Schreiber</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR:</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Febbo</FONT></I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Febbo</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>wjfebbo@gmail.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>ex10-3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIFEMD,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NON-QUALIFIED
STOCK OPTION AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
NON-QUALIFIED STOCK OPTION is granted as of June 20, 2023 (the &ldquo;<B>Grant Date</B>&rdquo;), and reflected in this NON-QUALIFIED
STOCK OPTION AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;) by and between LifeMD, Inc. (the &ldquo;<B>Company</B>&rdquo;) and William
Febbo the &ldquo;<B>Optionee</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
pursuant to the authority of the Board of Directors (the &ldquo;<B>Board</B>&rdquo;), the Company has granted the Optionee the right
to purchase common stock, $0.01 par value per share (&ldquo;<B>Common Stock</B>&rdquo;) of the Company pursuant to stock options, at
not less than 100% of fair market value, granted under the LifeMD, Inc. 2020 Equity and Incentive Plan and any Amendments thereto, approved
by the Board (the &ldquo;Plan&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW
THEREFORE, in consideration of the mutual covenants and promises hereafter set forth and other good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Grant of Non-Qualified Options</U>. The Company hereby irrevocably grants to the Optionee, as a matter of separate agreement and not
in lieu of salary or other compensation for services, the right and option to purchase all or any part of an aggregate of Thirty Seven
Thousand Five Hundred (37,500) shares of authorized but unissued or treasury common stock of the Company (the &ldquo;<B>Options</B>&rdquo;)
on the terms and conditions herein set forth. The Options are not intended to be Incentive Stock Options as defined by Section 422 of
the Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Price</U>. The exercise price of the shares of Common Stock subject to the Options granted hereunder shall be $3.37 (closing price
day of execution; or, if executed pre-market, the prior business day&rsquo;s closing price).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Vesting</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Options shall vest on the two-year anniversary of the Grant Date, subject to the terms herein and the Optionee continuing to perform
services for the Company on each applicable vesting date. Notwithstanding the foregoing, the Options shall vest upon the termination
of the services provided to the Company by Optionee in her capacity as a director of the Company on account of being removed from such
role or otherwise not being asked to stand for re-election for reasons other than Cause (as that term is defined in a service and/or
director agreement of such Optionee, or if such term or terms is not defined in a service and/or director agreement or there is not a
service agreement, as defined by the Plan). If terminated for Cause, the Options shall vest in a pro rata fashion up until the point
of time that served as the basis for termination for Cause. Similarly, in the case of death or disability, the Options shall vest in
a pro rata fashion up until the point in time of death or disability. In lieu of fractional vesting, the number of Options shall be rounded
up each time until fractional Options are eliminated. In addition, all of the Options shall, to the extent it is then unvested, vest
immediately prior to the closing for any Change of Control. As used herein, &ldquo;Change of Control&rdquo; means: (i) a bona fide transfer
or series of related transfers of Shares to any person or Group in which, or as a result of which, such person or Group obtains the direct
or indirect right to elect a majority of the board of directors of the Company; or (ii) a sale of all or substantially all of the assets
of the Company. As used herein, &ldquo;Group&rdquo; means any group or syndicate that would be considered a &ldquo;person&rdquo; for
purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Subject to Sections 3(c) and 4 of this Agreement, Options may be exercised by providing to the Company the Notice of Option Exercise
in the form attached hereto as <U>Exhibit A</U> after vesting and remain exercisable until 5:30 p.m. New York time on the date that is
the fifth (5th) year anniversary of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
However, notwithstanding any other provision of this Agreement, at the option of the Board in its sole and absolute discretion, all Options
shall be immediately forfeited in the event any of the following events occur:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Optionee purchases or sells securities of the Company without written authorization in accordance with the Company&rsquo;s insider
trading policy then in effect, if any;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Optionee (A) discloses, publishes or authorizes anyone else to use, disclose or publish, without the prior written consent of the
Company, any proprietary or confidential information of the Company, including, without limitation, any information relating to existing
or potential customers, business methods, financial information, trade or industry practices, sales and marketing strategies, employee
information, vendor lists, business strategies, intellectual property, trade secrets or any other proprietary or confidential information
or (B) directly or indirectly uses any such proprietary or confidential information for the individual benefit of the Optionee or the
benefit of a third party;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
During the term of service and for a period of one (1) year thereafter, the Optionee disrupts or damages, impairs, or interferes with
the business of the Company or its Affiliates by recruiting, soliciting or otherwise inducing any of their respective employees to enter
into employment or other relationship with any other business entity, or terminate or materially diminish their relationship with the
Company or its Affiliates, as applicable. Notably, Director has pre-existing relationships, as well as those created through the ordinary
course of business, from Director&rsquo;s work with the Boston Children&rsquo;s Hospital, Harvard Medical School, iSelect Fund, Virtue
Foundation, and others&mdash;none of which will be deemed a violation of this provision or this Agreement now or into the future, so
long as there is no malicious intent to violate this Agreement through such pre-existing relationships;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
During the term of employment and for a period of one (1) year thereafter, the Optionee solicits or directs business of any person or
entity who is (A) a customer of the Company or its Affiliates at any time or (B) solicited to be a &ldquo;prospective customer&rdquo;
of the Company or its Affiliates, in any case either for such Optionee or for any other person or entity. For purposes of this clause
(v), &ldquo;<B>prospective customer</B>&rdquo; means a person or entity who contacted, or is contacted by, the Company or its Affiliates
regarding the provision of services to or on behalf of such person or entity; <I>provided </I>that the Optionee has actual knowledge
of such prospective customer. Notably, Director has pre-existing relationships, as well as those created through the ordinary course
of business, from Director&rsquo;s work with the Boston Children&rsquo;s Hospital, Harvard Medical School, iSelect Fund, Virtue Foundation,
and others&mdash;none of which will be deemed a violation of this provision or this Agreement now or into the future, so long as there
is no malicious intent to violate this Agreement through such pre-existing relationships.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Optionee fails to reasonably cooperate to effect a smooth transition of the Optionee&rsquo;s duties and to ensure that the Company
is apprised of the status of all matters the Optionee is handling or is unavailable for consultation after termination of employment
of the Optionee if such availability is a condition of any agreement to which the Company and the Optionee are parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The Optionee fails to assign all of such Optionee&rsquo;s rights, title and interest in and to any and all ideas, inventions, formulas,
source codes, techniques, processes, concepts, systems, programs, software, computer data bases, trademarks, service marks, brand names,
trade names, compilations, documents, data, notes, designs, drawings, technical data and/or training materials, including improvements
thereto or derivatives therefrom, whether or not patentable or subject to copyright or trademark or trade secret protection, developed
and produced by the Optionee used or intended for use by or on behalf of the Company or the Company&rsquo;s clients; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The Optionee acts in a disloyal manner to the Company, such as making comments, whether oral or in writing, that tend to disparage or
injure (i) the reputation or business of the Company or its Affiliates, or is likely to result in discredit to, or loss of business,
reputation, or goodwill of, the Company or its Affiliates or (ii) its directors, officers, or stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, all of the Options shall, to the extent then unvested, vest immediately prior to the closing for any Change of Control. As
used herein, &ldquo;<B>Change of Control</B>&rdquo; means (i) a bona fide transfer or series of related transfers of shares of Common
Stock to any person or Group in which, or as a result of which, such person or Group obtains the direct or indirect right to elect a
majority of the board of directors of the Company; or (ii) a sale of all or substantially all of the assets of the Company. As used herein,
&ldquo;<B>Group</B>&rdquo; means any group or syndicate that would be considered a &ldquo;person&rdquo; for purposes of Section 13(d)
of the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
For purposes of this Agreement, &ldquo;<B>Affiliate</B>&rdquo; means with respect to a person or entity, any other person or entity controlled
by, in control of or under common control with such person or entity, and &ldquo;controlled,&rdquo; &ldquo;controlled by,&rdquo; and
&ldquo;under common control with&rdquo; shall mean direct or indirect possession of the power to direct or cause the direction of management
or policies (whether through ownership of voting securities, by contract or otherwise) of a person or entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Representations and Warranties; Acknowledgements. In connection with the grant of the Award Shares hereunder, Optionee represents and
warrants to the Company that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Optionee is able to bear the economic risk of Optionee&rsquo;s investment in the Shares for an indefinite period of time because the
Award Shares have not been registered under the Securities Act and, therefore, cannot be sold unless subsequently registered under the
Securities Act or an exemption from such registration is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Optionee and Optionee&rsquo;s advisers have had an opportunity to ask questions and receive answers concerning the terms and conditions
of the offering of the Shares as Optionee and Optionee&rsquo;s advisers have requested and have had full and free access and opportunity
to inspect, review, examine, and inquire about such other information concerning the Company and its Affiliates as they have requested.
Optionee and Optionee&rsquo;s advisers have also been provided an opportunity to review and ask questions about the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Optionee has had an opportunity to consult with independent legal counsel regarding Optionee&rsquo;s rights and obligations under this
Agreement and the Plan, and fully understands the terms and conditions contained herein. Optionee is not relying on the Company or any
of its Optionees, agents, or representatives with respect to the legal, tax, economic, and related considerations of an investment in
the Shares. Optionee understands that in the future the Shares may significantly increase or decrease in value, and the Company has not
made any representation to the Optionee about the potential future value of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Optionee understands and agrees that the investment in the Company involves a high degree of risk and that no guarantees have been made
or can be made with respect to the future value of the Award Shares or the future profitability or success of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
Termination of Relationship. Upon the Optionee&rsquo;s termination of service, all unvested Options shall be automatically and irrefutably
forfeited. For purposes of this Agreement, terms like &ldquo;service&rdquo; and &ldquo;termination of service&rdquo; refer to service
with the Company and all Affiliates of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If for any reason, except death or disability as provided below, the Optionee ceases to perform the services for which the Options were
granted, the Optionee shall have the right within three (3) months from the date of cessation to exercise the Optionee&rsquo;s vested
Options, subject to Section 3(c) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
If the Optionee shall die while performing services for the Company, such Optionee&rsquo;s estate or any Transferee (as defined hereinafter)
shall have the right within twelve (12) months from the date of death to exercise the Optionee&rsquo;s vested Options, subject to Section
3(c) hereof. For the purpose of this Agreement, &ldquo;<B>Transferee</B>&rdquo; shall mean an individual to whom such Optionee&rsquo;s
vested Options are transferred by will or by the laws of descent and distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If the Optionee shall become disabled while performing services for the Company within the meaning of Section 22(e)(3) of the Code, the
three-month period referred to in Section 4(a) of this Agreement shall be extended to one year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
For purposes of this Agreement, a change from performing service on the Board to an employment or consulting relationship or vice versa
shall not be treated as a termination of service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Profits on the Sale of Certain Shares; Redemption</U>. If any of the events specified in Section 3(c) of this Agreement occur within
one (1) year from the last date the Optionee performed services for which the Options were granted (the &ldquo;<B>Termination Date</B>&rdquo;),
all profits earned from the sale of the Company&rsquo;s securities, including the sale of shares of Common Stock underlying the Options,
during the two (2) year period commencing one (1) year prior to the Termination Date shall be forfeited and forthwith paid by the Optionee
to the Company within ten (10) days after the Optionee receives written demand from the Company for such payment and a copy of the documentation
of the sale, including, without limitation, the purchase price therefor. Further, in such event, the Company may at its option redeem
shares of Common Stock acquired upon exercise of the Options by payment of the exercise price to the Optionee. The Company&rsquo;s rights
under this Section 5 do not lapse one year from the Termination Date, but are a contract right subject to any appropriate statutory limitation
period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Transfer</U>. No transfer of the Options by the Optionee by will or by the laws of descent and distribution shall be effective to
bind the Company unless the Company shall have been furnished with written notice thereof and a copy of the letters testamentary or such
other evidence as the Board may deem necessary to establish the authority of the estate and the acceptance by the Transferee or Transferees
of the terms and conditions of the Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Method of Exercise</U>. The Options shall be exercisable by a written notice in the manner and form identified on Exhibit A hereto
which information shall include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
state the election to exercise the Options, the number of shares to be exercised, the natural person in whose name the stock certificate
or certificates for such shares of Common Stock is to be registered and such person&rsquo;s address and social security number (or if
more than one, the names, addresses and social security numbers of such persons);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
contain such representations and agreements as to the holder&rsquo;s investment intent with respect to such shares of Common Stock as
set forth in Section 11 hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
be signed by the person or persons entitled to exercise the Options and, if the Options are being exercised by any person or persons
other than the Optionee, be accompanied by proof, satisfactory to counsel for the Company, of the right of such person or persons to
exercise the Options; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
be accompanied by full payment of the purchase or exercise price and all applicable required tax withholding in United States dollars
in cash or by bank or cashier&rsquo;s check, certified check or money order or (i) by executing a &ldquo;sell-to-cover cashless exercise&rdquo;
through the Company&rsquo;s designated broker to promptly deliver to the Company the amount of proceeds from the sale of shares having
a fair market value equal to the purchase price and all applicable required tax withholding on the date of exercise; (ii) by executing
a &ldquo;net cashless exercise&rdquo; by having the Company withhold Option shares equivalent in value to the exercise price and all
applicable required tax withholding; or (iii) by tendering shares of Common Stock equivalent in value to the exercise price and all applicable
required tax withholding, subject to applicable securities laws and share holding period requirements necessary to avoid a charge to
the Company&rsquo;s earnings for financial accounting purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate or certificates for shares of Common Stock as to which the Options shall be exercised shall be registered in the name of
the person or persons exercising the Options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Sale of Shares Acquired Upon Exercise of Options</U>. If the Optionee is an officer (as defined by Section 16(b) of the Securities
Exchange Act of 1934, as amended (&ldquo;<B>Section 16(b)</B>&rdquo;), any shares of the Company&rsquo;s Common Stock acquired pursuant
to Options granted hereunder cannot be sold by the Optionee, subject to registration or an exemption from registration such as to Rule
144 promulgated under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), until at least six (6) months
elapse from the date of grant of the Options, except in the case of death or disability or if the grant was exempt from the short-swing
profit provisions of Section 16(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Adjustments</U>. The Options under this Agreement shall be subject to the terms of the Plan, including but not limited to, Sections
3(b) (Changes in Stock) and 3(c) (Sale Events) of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Necessity to Become Holder of Record</U>. Neither the Optionee, the Optionee&rsquo;s estate, nor the Transferee have any rights as
a shareholder with respect to any shares of Common Stock covered by the Options until such Optionee, estate or Transferee, as applicable,
shall have become the holder of record of such shares of Common Stock. No adjustment shall be made for cash dividends or cash distributions,
ordinary or extraordinary, in respect of such shares of Common Stock for which the record date is prior to the date on which such Optionee,
estate or Transferee, as applicable, shall become the holder of record thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Conditions to Exercise of Options</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In order to enable the Company to comply with the Securities Act and relevant state law, the Company may require the Optionee, the Optionee&rsquo;s
estate or any Transferee, as a condition of the exercise of the Options granted hereunder, to give written assurance satisfactory to
the Company that the shares of Common Stock subject to the Options are being acquired for such Optionee&rsquo;s, estate&rsquo;s or Transferee&rsquo;s,
as applicable, own account, for investment only, with no view to the distribution of same, and that any subsequent resale of any such
shares of Common Stock either shall be made pursuant to a registration statement under the Securities Act and applicable state law which
has become effective and is current with regard to the shares of Common Stock being sold, or shall be pursuant to an exemption from registration
under the Securities Act and applicable state law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Options are subject to the requirement that, if at any time the Board shall determine, in its sole and absolute discretion, that
the listing, registration or qualification of the shares of Common Stock subject to the Options upon any securities exchange or under
any state or federal law, or the consent or approval of any governmental regulatory body, is necessary as a condition of, or in connection
with the issue or purchase of such shares of Common Stock under the Options, the Options may not be exercised in whole or in part unless
such listing, registration, qualification, consent or approval shall have been effected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Severability</U>. In the event any parts of this Agreement are found to be void, the remaining provisions of this Agreement shall
nevertheless be binding with the same effect as though the void parts were deleted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Arbitration</U>. Any controversy, dispute or claim arising out of or relating to this Agreement, or its interpretation, application,
implementation, breach or enforcement which the parties hereto are unable to resolve by mutual agreement, shall be settled by submission
by either party of the controversy, claim or dispute to binding arbitration in New York County, New York (unless the parties agree in
writing to a different location), before a single arbitrator in accordance with the rules of the American Arbitration Association then
in effect. The decision and award made by the arbitrator shall be final, binding, and conclusive on all parties hereto for all purposes,
and judgment may be entered thereon in any court having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Benefit</U>. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their legal representatives,
successors, and assigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<U>Notices and Addresses</U>. All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing,
and shall be sufficiently given if delivered to the addressees in person, by FedEx or similar receipted delivery, or by facsimile delivery
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Optionee:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Febbo </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>wjfebbo@gmail.com</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">236
    Fifth Avenue, Suite 400</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10001</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>legal@lifemd.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or
to such other address as either of them, by notice to the other, may designate from time to time. The transmission confirmation receipt
from the sender&rsquo;s facsimile machine shall be evidence of successful facsimile delivery. Time shall be counted to, or from, as the
case may be, the delivery in person or by mail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<U>Attorney&rsquo;s Fees</U>. In the event that there is any controversy or claim arising out of or relating to this Agreement, or to
the interpretation, breach, or enforcement thereof, and any action or proceeding is commenced to enforce the provisions of this Agreement,
the prevailing party shall be entitled from the non-prevailing party to its reasonable attorneys&rsquo; fee, costs, and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<U>Governing Law</U>. This Agreement and any dispute, disagreement, or issue of construction or interpretation arising hereunder whether
relating to its execution, its validity, the obligations provided herein or performance, shall be governed or interpreted according to
the laws of the State of Delaware without regard to choice of law considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<U>Oral Evidence</U>. This Agreement, along with the Plan, a director and/or employment agreement, and any amendment thereto, constitute
the entire agreement between the parties hereto and supersedes all prior oral and written agreements between the parties hereto with
respect to the subject matter hereof. Neither this Agreement nor any provision hereof may be changed, waived, discharged, or terminated
except by a statement in writing signed by the party or parties against which enforcement or the change, waiver discharge or termination
is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of
which together shall constitute one and the same instrument. The execution of this Agreement may be made by facsimile signature, which
shall be deemed to be an original.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<U>Section Headings</U>. Section headings herein have been inserted for reference only and shall not be deemed to limit or otherwise
affect, in any matter, or be deemed to interpret in whole or in part, any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the parties hereto have set their hand the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIFEMD,
    INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Justin Schreiber</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
    Schreiber</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPTIONEE:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Febbo</FONT></I></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">William
    Febbo</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
page to Non-qualified Stock Option Agreement]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
OF NOTICE OF OPTION EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:
LifeMD, Inc. (the &ldquo;Company&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase __________ shares of Common Stock of the Company (the &ldquo;Shares&rdquo;) pursuant to the
terms of the Option Agreement by and between the Company and the undersigned dated as of __________ ___, 20__, and tenders herewith payment
of the exercise price in full as set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    ]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    lawful money of the United States in the form of cash or by a bank check or cashier&rsquo;s check made payable by the undersigned
    to the Company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    ]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    lawful money of the United States in the form of a wire transfer to the account specified by the Company;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    ]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the form of shares of a &ldquo;broker-assisted cashless exercise&rdquo; as described in Section 7(d) of the Option Agreement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    ]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the form of shares of a &ldquo;net cashless exercise&rdquo; as described in Section 7(d) of the Option Agreement; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
    ]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    the form of shares of Common Stock (a &ldquo;stock-for-stock exercise&rdquo;) as described in Section 7(d) of the Option Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue a certificate or certificates representing the Shares in the name of the undersigned or in such other name as is specified
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">____________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Shares shall be delivered via overnight courier (with tracking information to be provided to the undersigned) to the following address:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 34%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    __________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    ___________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OPTIONEE</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">__________________________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Exhibit
A to Non-qualified Stock Option Agreement]</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>ex10-4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>CONSULTING
SERVICES AGREEMENT</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Consulting Services Agreement (&ldquo;Consulting Agreement&rdquo; or the &ldquo;Agreement&rdquo;) is made effective as of May 30, 2023
(the &ldquo;Effective Date&rdquo;), by and between William Febbo, having an address at 142 Calle Violeta, San Juan, Puerto Rico 00927
(the &ldquo;Consultant&rdquo;) and LifeMD, Inc., a corporation with an address of 236 Fifth Avenue, Suite 400, New York, NY 10001 (the
&ldquo;Company&rdquo;) (the Company and Consultant together the &ldquo;Parties&rdquo; or individually a &ldquo;Party&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
the Company and the Consultant desire to enter into this Consulting Agreement, pursuant to which the Consultant will provide services
as a Consultant to the Company, subject to the terms and conditions set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the mutual covenants and obligations contained herein, the Company and the Consultant, intending to be
legally bound, hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A.
 <U>Engagement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Consultant shall provide the Services defined below in Section C herein for the Company, reporting to Justin Schreiber, Chairman &amp;
CEO of LifeMD (the &ldquo;Engagement&rdquo;). In this capacity, the Consultant agrees to devote its best efforts, energies, and skill
to the full discharge of its duties and responsibilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>B. <U>Commencement,
Initial &amp; Extended Terms, and Termination</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Commencement;
Initial &amp; Extended Terms</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Services
under this Consulting Agreement commenced on May 30, 2023 (the &ldquo;Commencement Date&rdquo;) and shall continue until November 30,
2024 (the &ldquo;Initial Term&rdquo;) unless terminated. The Parties, through mutual consent to do so, may choose to renew this Agreement
for the same length of time as the Initial Term or some other mutually agreed upon length of time on or before the expiration of the
then existing Term (the &ldquo;Extended Term&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Termination</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
Party may, upon 14 days written notice to the other Party, terminate this Agreement at any time for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C. <U>Services
to be Performed</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
  During the Term of this Consulting Agreement, the Consultant shall serve the Company for board
services, including but not limited to providing the following services:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
                                            Relations </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Introductions
                                            to institutional investors</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guidance
                                            on the Company&rsquo;s investor relations strategy, investor positioning, and materials used
                                            for presentations to investors</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Strategic
                                            Business Development</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Introductions
                                            to pharmaceutical and other healthcare product companies</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Introductions
                                            to pharma services providers, agencies, and other entities that can support the enterprise
                                            sales objectives of LifeMD</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Guidance
                                            around positioning of LifeMD&rsquo;s enterprise offering, pricing strategy, and overall commercialization
                                            strategy within the healthcare product world</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. The
Consultant will use the highest degree of skill and expertise to accomplish the Services within the Initial Term, and any Extended Term(s),
of this Agreement professionally and ethically, and to project a positive image of the Company, in accordance with the Company&rsquo;s
policies and procedures, and applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>D.
 <U>Compensation for Services</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Compensation
for Consulting Services</U>. The Company shall pay Consultant 375,000 shares of LifeMD restricted common stock, according to the following
schedule:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,500
                                            shares on August 30, 2023</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,500
                                            shares on November 30, 2023</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,500
                                            shares on February 30, 2024</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,500
                                            shares on May 30, 2024</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,500
                                            shares on August 30, 2024</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,500
shares on November 30, 2024 All of the Compensation to the extent it is then unvested, shall vest immediately prior to the closing for
any Change of Control. As used herein, &ldquo;Change of Control&rdquo; means: (i) a bona fide transfer or series of related transfers
of Shares to any person or Group in which, or as a result of which, such person or Group obtains the direct or indirect right to elect
a majority of the board of directors of the Company; or (ii) a sale of all or substantially all of the assets of the Company. As used
herein, &ldquo;Group&rdquo; means any group or syndicate that would be considered a &ldquo;person&rdquo; for purposes of Section 13(d)
of the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Entire
Compensation</U>. Consultant acknowledges that the foregoing provisions of this Section D constitute the sole and entire compensation
payable to it for the Engagement and the provision of the Services of Consultant, and the Parties specifically agree that no compensation,
benefits, or other reimbursements of any other nature are required to be paid or payable to Consultant as a result of the provision of
Services hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
<FONT STYLE="font-weight: normal"> </FONT><U>Ownership of Materials</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Ownership</U>.
All materials, reports, plans, information, ideas, inventions, discoveries, improvements, methods, processes, drawings, renditions, mock-ups,
prototypes, creative execution, advertising ideas, creative concepts, or other works conceived, created, reduced to practice, delivered,
or disclosed to the Company or produced or otherwise arising out of the Services, in whole or in part and whether alone or in conjunction
with others (whether or not during work hours devoted to the Services) (collectively, the &ldquo;Creative Materials&rdquo;), and all
rights, title, and interests (including copyrights) in and to such Creative Materials throughout the world, are hereby assigned to the
Company and shall be the sole and exclusive property of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Works
Made for Hire</U>. All copyrightable works comprising the Creative Materials shall be considered &ldquo;works made for hire&rdquo; as
defined in the United States Copyright Act, whether published or unpublished, and all rights, title, and interest to all such copyrightable
works shall be the exclusive property of the Company, and the Company shall be deemed to be the author and owner of such copyrightable
works. Consultant shall not distribute the copyrightable works, in part or in entirety, to any third party without the express written
consent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
 <U>Disclosure; Cooperation</U>. Consultant shall promptly disclose all such Creative Materials
to the Company, and the Company shall have full power and authority to file any patent or copyright registrations, or other intellectual
property submissions, applications, or registrations throughout the world thereon and to procure and maintain any patents, copyrights,
or other intellectual property rights thereon. Consultant agrees, at the Company&rsquo;s reasonable request and expense, to execute any
applications, assignments, instruments, and other documents, and perform such acts, as the Company may deem necessary or advisable to
confirm and vest in the Company all such rights, title and interests throughout the world in and to such Creative Materials and all intellectual
property rights pertaining thereto, and to assist the Company in procuring, maintaining, enforcing, and defending such intellectual property
rights and protection throughout the world thereon. To the extent not covered by the foregoing, The Company shall have the fully paid-up
and irrevocable right to use and disclose freely and for any purpose all information and ideas disclosed by Consultant to the Company
in performing the Services hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <U>Consultant&rsquo;s
Obligations</U>. With respect to any Creative Materials, Consultant shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Treat
                                            all information with respect thereto as Confidential Information of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Keep
                                            complete and accurate records thereof, which records shall be the property of the Company;
                                            and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
                                            time to time, upon the request and at the expense of the Company, but without payment to
                                            Consultant by the Company of additional consulting fees, execute all assignment or other
                                            instruments required to transfer and assign to the Company (or as it may direct) all Creative
                                            Materials, and all patents and applications for patents, copyrights, or applications for
                                            registration of copyrights, covering such inventions or otherwise required to protect the
                                            rights and interests of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>F.</B> <B><U>Confidentiality</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Confidential
Information</U>. Consultant acknowledges that it may be necessary for the Company during the course of the Engagement, to disclose certain
confidential and proprietary information (&ldquo;Confidential Information&rdquo;) to Consultant, in order for Consultant to perform the
Services pursuant to this Agreement. Consultant shall not disclose or use, at any time either during or after the Term of this Agreement,
for their own benefit or for the benefit of any third party, any Confidential Information without the Company&rsquo;s prior written permission
except to the extent necessary to perform the Services on the Company&rsquo;s behalf. Confidential Information includes, without limitation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
                                            written, printed, graphic, or electronically recorded materials furnished by the Company
                                            for Consultant to use; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Any
                                            written or tangible information stamped &ldquo;confidential,&rdquo; &ldquo;proprietary,&rdquo;
                                            or with a similar legend or any information that the Company makes reasonable efforts to
                                            maintain its secrecy; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Business,
                                            research and development, regulatory, and marketing plans; objectives and/or strategies;
                                            financial information; corporate initiatives; contractual and business arrangements; customer
                                            and supplier lists; sales projections; product information and launch plans; regulatory submissions;
                                            and pricing information of the Company and its affiliates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Information,
                                            data, test results, patent applications, methodologies, operating procedures, trade secrets,
                                            design formulas, know-how, techniques, analyses, technology, processes, protocols, specifications,
                                            and instructions relating to the Company&rsquo;s proprietary products, including safety data
                                            and reference standards, investigators brochures, documents and reports, computer programs
                                            and inventories, discoveries and improvements of any kind, sales projections, product information,
                                            and pricing information of the Company and its affiliates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Information,
                                            know-how, trade secrets, materials, and tangible property belonging to customers and suppliers
                                            of the Company and other third parties who have disclosed such confidential and proprietary
                                            information to the Company about whom Consultant gained knowledge as a result of providing
                                            Services to the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Any
                                            data, deliverables, or other work product or information generated or developed by Consultant
                                            in connection with the performance of Services under this Agreement, including all Creative
                                            Materials; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(g)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Any
                                            copies, extracts, notes, or summaries of any information described in clauses (a) through
                                            (f).</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Notwithstanding
any of the foregoing, Confidential Information shall not include any information that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">is
                                            or becomes available in the public domain through no fault of, or act or failure to act on
                                            the part of, Consultant; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">is
                                            rightfully in Consultant&rsquo;s possession at the time of disclosure by the Company, as
                                            evidenced by Consultant&rsquo;s written records maintained in the ordinary course of business;
                                            or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">is
                                            obtained, after the Effective Date, by Consultant from any third party that is lawfully in
                                            possession of such Confidential Information and not in violation of any contractual or legal
                                            obligation with respect to such Confidential Information. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. At
any time upon request of the Company or upon Termination of this Agreement, Consultant shall promptly deliver to the Company: (i) all
Confidential Information (and all copies thereof) and all other property furnished to Consultant, by the Company and all other materials
prepared by Consultant, containing any Confidential Information; and (ii) a certification that all Confidential Information has been
delivered to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Notwithstanding
the return of Confidential Information or the Termination of this Agreement, Consultant, will continue to be bound by the obligations
of confidentiality pursuant to this Section F. In addition to its other legal rights, the Company shall be entitled to temporary and
permanent injunctive relief and specific performance to remedy any breach or attempted breach of this Section F of the Agreement, and
in the event the Company prevails in any action brought under this Section F, the Company shall also be entitled to recover its reasonable
attorney&rsquo;s fees and costs expended in such action from Consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>G.
 <U>Non-Solicitation; Non-Disparagement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <U>Non-Solicitation</U>.
Consultant covenants and agrees that during the term of this Agreement, and for a two (2) year period immediately following the termination
of this Agreement, regardless of the reason therefor, the Consultant shall not solicit, induce, aid, or suggest to: (a) any employee
to leave such employ, (b) any contractor, consultant, or other service provider to terminate such relationship, or (b) any customer,
agency, vendor, or supplier of the Company to cease doing business with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <U>Non-Disparagement</U>.
The Consultant will not make any remarks or adverse statements, in any and all media (<I>e.g.</I>, in writing, orally or on the internet
via, among other things, blogs, message boards and social networks), about the Company or its affiliates that could reasonably be construed
as disparaging or defamatory, or to cast the Company or any of its affiliates in a negative light or harm the Company&rsquo;s or any
of its affiliates&rsquo; current or prospective business plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>H. <U>RESERVED.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>I.
</B> <B><U>Indemnification</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. The
Company agrees to defend, indemnify, and hold Consultant harmless from and against any and all claims, liabilities, losses, damages,
and expenses arising out of: (a) any breach by the Company of its warranties, representations, covenants, and obligations outlined in
this Agreement; and (b) the gross negligence or willful misconduct of the Company; and (c) the failure of the Company to comply with
all legal requirements to the best of its knowledge at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Consultant
agrees to defend, indemnify, and hold the Company harmless from and against any and all claims, liabilities, losses, damages, and expenses
arising out of: (a) any breach by Consultant of his warranties, representations, covenants, and obligations outlined in this Agreement;
(b) the gross negligence or willful misconduct of Consultant; and (c) the failure of Consultant to comply with all legal requirements
to the best of his knowledge at the time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. The
Parties further agree that they shall not, without the prior written consent of the other Party, settle, compromise, or consent to the
entry of any judgment in any pending or threatened claim, action, suit or proceeding in respect of which defense and/or indemnification
may be sought hereunder unless such settlement, compromise, or consent includes an unconditional release of the Party seeking defense
and/or indemnity from all liability arising out of such claim, action, suit, or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. The
Party seeking defense or indemnification hereunder shall: (i) promptly notify the other Party of the matter for which defense or indemnification
is sought; (ii) subject to the immediately preceding sentence of this paragraph, provide the other Party with sole control over the defense
and/or settlement thereof, including but not limited to the selection of counsel; and (iii) at the request of the Party providing defense
and/or indemnification, fully cooperate in the provision of full and complete information and reasonable assistance with respect to the
defense of such matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>J. <U>Survival</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
obligations of the Parties pursuant to Sections E, F, G, and J shall survive the Termination of this Agreement, regardless of the reason
for such Termination, along with any and all other provisions that expressly provide for survival of Termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>K.
 <U>Relationship of the Parties; Independent Contractor Status</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties agree that the relationship created by this Engagement is one of an independent contractor. The Parties further agree that Consultant,
are not and shall not be considered employees of the Company and are not and shall not be entitled to any of the rights and/or benefits
that the Company provides for the Company&rsquo;s employees (including any employee pension, health, vacation pay, sick pay, or other
fringe benefits offered by the Company under plan or practice) by virtue of the Services being rendered by Consultant. Consultant acknowledges
and agrees that the Company does not, and shall not, maintain or procure any workers&rsquo; compensation or unemployment compensation
insurance for or on behalf of Consultant, and shall make no state temporary disability or family leave insurance payments on behalf of
Consultant, and Consultant agrees that Consultant will not be entitled to these benefits in connection with performance of the Services
under this Agreement. Consultant acknowledges and agrees that it shall be solely responsible for paying all salaries, wages, benefits,
and other compensation which Consultant, may be entitled to receive in connection with the performance of the Services under this Agreement.
Consultant is responsible for all taxes, if any, imposed on it in connection with its performance of Services under this Agreement, including
any federal, state, and local income, sales, use, excise, and other taxes or assessments thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>L.
 <U>Binding Nature; Assignments</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors, representatives, administrators,
heirs, executors, and permitted assigns, except that the duties of Consultant are personal and shall not be assigned or subcontracted
without the Company&rsquo;s prior written consent and any purported assignment without such written consent shall be deemed void and
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>M.
 <U>Entire Agreement; Amendments</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement contains the entire understanding between the Parties with respect to its subject matter and supersedes all previous negotiations,
agreements, or understandings between the Parties&mdash;as well as between Consultant and Cleared&mdash;whether written or verbal. This
Agreement may not be amended or modified, except in writing, executed by duly authorized representatives of the Parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N.
 <U>Governing Law; Consent to Jurisdiction and Venue</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be governed by and construed in accordance with the laws of New York, without giving effect to principles of conflicts
of laws. The Parties agree that any dispute concerning or arising under this Agreement shall be subject to the exclusive jurisdiction
of the state and federal courts of New York, and each Party agrees to submit to the personal and exclusive jurisdiction and venue of
such courts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>O.
 <U>Notices</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices required or permitted to be delivered under this Agreement shall be in writing and sent to the principal place of business of
the Party to whom they are addressed. Notices to Consultant shall be delivered to the attention of Consultant. Notices to the Company
shall be delivered to the attention of the CEO and General Counsel (legal@lifemd.com). All notices under this Agreement shall be deemed
delivered only if sent by overnight mail or courier with return receipt, or email with read receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>P.
 <U>Severability</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any provision of this Agreement is found to be invalid or unenforceable for any reason by a court of competent jurisdiction, that provision
shall be stricken from this Agreement and that finding shall not invalidate any other terms of this Agreement, which terms shall remain
in full force and effect according to the surviving terms of this Agreement. In such an event, the Parties shall negotiate with one another
to agree on a provision which the Parties would have agreed if they had known of the defect when they signed this Agreement, in order
to achieve the same commercial outcome and objectives of this Agreement that were intended upon its execution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Q.
 <U>Dispute Resolution</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any dispute arising under or pursuant to this Agreement, the Parties agree to attempt to resolve the dispute in a commercially
reasonable fashion before instituting any litigation or arbitration (except for emergency injunctive relief). If the parties are unable
to resolve the dispute within thirty (30) days, then the parties agree to mediate the dispute with a mutually agreed upon mediator in
New York, NY. If the parties cannot agree upon a mediator within ten (10) days after either party shall first request commencement of
mediation, each party will select a mediator within five (5) days thereof, and those mediators shall select the mediator to be used.
The mediation shall be scheduled within thirty (30) days following the selection of the mediator. The parties further agree that any
applicable statute of limitations will be tolled for the period from the date mediation is requested until 14 days following the mediation.
If the mediation does not resolve the dispute, then the parties irrevocably and unconditionally agree to the arbitration provisions in
Paragraph R below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>R.
 <U>Arbitration</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure the rapid and economical resolution of disputes that may arise in connection with this Agreement, Consultant and the Company agree
that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from
or relating to the enforcement, breach, performance, or interpretation of this Agreement, Consultant&rsquo;s consulting with the Company,
or the termination of this Agreement, shall be resolved pursuant to the employment arbitration rules and procedures under the Federal
Arbitration Act, 9 U.S.C. &sect; 1-16, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted
by JAMS or its successor, under JAMS&rsquo; then applicable rules and procedures for disputes (available upon request and also currently
available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U> ). Consultant agrees that the use of the JAMS rules and procedures
does not change Consultant&rsquo;s classification to that of an employee. To the contrary, Consultant reaffirms that the Consultant is
an independent contractor. The arbitration will take place in New York, NY unless otherwise agreed to by the Parties. Consultant acknowledges
that by agreeing to this arbitration procedure, both Consultant and the Company waive the right to resolve any such dispute through a
trial by jury or judge or administrative proceeding. In addition, all claims, disputes, or causes of action under this section, whether
by Consultant or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class
member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.
The arbitrator may not consolidate the claims of more than one person or entity and may not preside over any form of representative or
class proceeding. To the extent that the preceding description regarding class claims or proceedings are found to violate applicable
law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather
than by arbitration. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter
of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the
California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not
permitted by applicable law(s) to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal Arbitration
Act or otherwise invalid (collectively, the &ldquo;<U>Excluded Claims</U>&rdquo;). In the event Consultant intends to bring multiple
claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will
remain subject to mandatory arbitration. Consultant will have the right to be represented by legal counsel at any arbitration proceeding.
The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief
as would otherwise be permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each
claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&rsquo;s essential findings and
conclusions on which the award is based. The arbitrator shall be authorized to award all relief that Consultant or the Company would
be entitled to seek in a court of law. Nothing in this Agreement is intended to prevent either Consultant or the Company from obtaining
injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>S. <U>Fees,
Costs, &amp; Damages</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any action is necessary to enforce the provisions of this Agreement, including any claims or demands, or to interpret this Agreement,
the prevailing Party shall be entitled to reasonable attorneys&rsquo; fees, costs, and disbursements in addition to any other relief
to which it may otherwise he entitled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any legal action or other proceeding is brought for the enforcement of this Agreement or any agreement or instrument delivered under
or in connection with this Agreement, or because of an alleged dispute, breach, default, or misrepresentation in connection with any
of the provisions of this Agreement, the successful or prevailing Party or Parties shall be entitled to recover reasonable attorneys&rsquo;
fees and other costs incurred in that action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>T.
 <U>Counsel</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties acknowledge and represent that, prior to the execution of this Agreement, they have had an opportunity to consult with their
respective counsel concerning the terms and conditions set forth herein. Additionally, Consultant represents that it has had an opportunity
to receive independent legal advice concerning the taxability of any consideration received under this Agreement. Consultant has not
relied upon any advice from the Company and/or its attorneys with respect to the taxability of any consideration received under this
Agreement. Consultant further acknowledges that the Company has not made any representations to Consultant with respect to tax issues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>U. <U>Force
Majeure</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
of the Parties shall be liable to the other for any delay or failure to perform hereunder, which delay or failure is due to causes beyond
the control of said Party, including, but not limited to acts of God; acts of the public enemy; acts of the United States of America
or any state, territory, or political subdivision thereof or of the District of Columbia; fires; floods; epidemics; quarantine restrictions;
strike; or freight embargoes. Notwithstanding the foregoing provisions of this Section, in every case the delay or failure to perform
must be beyond the control and without the fault or negligence of the Party claiming excusable delay.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>V. <U>Counterparts</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which when taken together
shall be construed as a single instrument. This Agreement may be executed by facsimile or other electronic transmissions, and signatures
on any facsimile or electronic transmission copy hereof shall be deemed authorized original signatures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[<I>Signature
Page Follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, this Consulting Agreement has been duly executed by or on behalf of the Parties as of its Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; font-weight: bold">CONSULTANT</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 49%; font-weight: bold; text-align: left">LIFEMD, INC.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><I>/s/ William Febbo</I></TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><I>/s/ Justin Schreiber</I></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">William Febbo</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Justin Schreiber</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Chairman &amp; CEO</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman,serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD
Appoints William J. Febbo to its Board of Directors</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEW
YORK, June 20, 2023 &ndash; <U>LifeMD, Inc.</U> (Nasdaq: LFMD)</B>, a leading provider of virtual primary care services, today announced
the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of <U>OptimizeRx</U> Corporation (Nasdaq: OPRX) to its
Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay
on therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;We
are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies,
and pioneering technology to improve the experience for healthcare providers and patients,&rdquo; said Justin Schreiber, Chairman and
Chief Executive Officer of LifeMD. &ldquo;Will&rsquo;s success in leading OptimizeRx&rsquo;s growth with investment in AI-driven optimization,
real-time marketing, and personalized patient engagement offers a particularly valuable perspective as we continue to scale our primary-care
business and pursue our mission to increase access to high-quality and affordable virtual care.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;I
know firsthand that providing patients with access to exceptional healthcare when and where they need it requires best-in-class technology,
clinical resources, and patient engagement,&rdquo; said Mr. Febbo. &ldquo;I am impressed by LifeMD&rsquo;s continued success with launching
new product offerings, building a B2B pipeline, and strengthening the balance sheet &ndash; each of which is necessary to help remove
the complex barriers that stand between a patient and appropriate healthcare provider. I look forward to collaborating with LifeMD&rsquo;s
Board and leadership to help make the delivery of healthcare services more accessible, affordable, and patient-centric.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more than 25 years Mr. Febbo has built and managed health services and financial businesses, starting in M&amp;A and international business
development at multinational companies. In 1999 he co-founded and subsequently served as Chief Executive Officer of MedPanel, a market
intelligence and communication provider to the life sciences and financial industries. In 2007 MedPanel was acquired by Merriman Capital,
where he served as Chief Operating Officer of investment banking and as Chief Executive Officer of the firm&rsquo;s Digital Capital Network.
In 2016 Mr. Febbo joined OptimizeRx, where he helped transform the firm into a leading digital health company enabling care-focused engagement
between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Febbo serves as a faculty member for the Massachusetts Institute of Technology linQ program, a collaborative initiative increasing the
potential of innovative biomedical research to benefit society and the economy. He also serves on the board of the United Nations of
Greater Boston, a non-profit organization focused on building a stronger network of global citizens in the Boston area.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
LifeMD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LifeMD
is a leading provider of virtual primary care. The Company offers telemedicine, laboratory and pharmacy services, and specialized treatment
across more than 200 conditions including primary care, men&rsquo;s health, women&rsquo;s health, allergy &amp; asthma, and dermatology.
Leveraging a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a US-based patient care
center, LifeMD is simplifying healthcare by increasing access to top-notch and affordable care. For more information, please visit <U>LifeMD.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Contact </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>press@lifemd.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marc
Benathen, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>marc@lifemd.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
# #</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  P *8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^XCX*?'#X
M7_M$^!;7XE_"3Q79^,_!=S?ZCI%OKNGV^H6<4FH:1-Y.JQYN(H)0(Y FUA$B
MEB561V.$]I9=K,Y.!V_''^?KQS7XY_\ !#@G_A@CPR.W_"S_ (H'\?\ A,9J
M_8TN&^5NXR,?_7_/CD?K79F^$6"S;-,OA?EHR<%=W?*KQM?2[U[+?T/&R7,)
M9ID^58[$V4JD%-]N9W5_ZOJ(& 4X'/7/_P"L>G\S7S/\%/VI_@5^T?KOQ2\/
M?"7QM;^*]7^#7B\>#O'5M;VNH6/]G:XS:U#"H>984UG3)GT?6HK=H&:%Y-'N
M PXA>OI@*"IP>>F/_P!9]/Y&O+? ?P<^%OPLU#QMJWP^\">&/!FI?$7Q"WBK
MQS=^'M(BTV3Q3XG:,HVLZQY( EN"I95D&5 <E2,G=S8?ZM["5D^6RY+6TUUY
MNNW;Y]SOK_6_K$?JW;WKW^7X]]>VMBW\3?BK\.?@QX2OO'?Q2\8Z!X%\):0J
MM?\ B#Q%>QZ?IL )X\R1SDEL':JAVX)QM)-?&&B?\%4_V"_$NMZ7X;T/]H7P
MUJ>L:_JVDZ+H]C'HOC -?:GKQ#:1%&S^'% \XC +,%!()(QN'C/[;G@C0OC#
M^W5_P3]^$OQ!M?\ A(OAC>_\+S\>:MX+O&CN_#6N>)O W@N+5] ?7-$F21-:
M2!G>18Y$900^4)D(/Z=6'P^\ Z5#'9:3X,\(:9%I@7['%IWAS2;(6F ,^7Y$
M(5&YSNC"$XSDX%=RPN68/"Y;]:52<I1YK*4(1II2<(<CE%^\W%R;=UJMEH_(
M>+S/%XO-(X1PBLGGR)23?M).*FTTNBB]-KK1/6QZ31117G'T(4444 0JV!N*
MA>.!GG^9X'<]NE#-D;@H;CD9Y_F.#V/?I7S/^TU\9=9^"'PYA\8Z#I6GZYJ1
MU_1]+>TU)I(XOL6KS/%(5965PZL(N,X(QD9%=A\'?C)X4^-?A2/Q-X8GVNNV
MUU+3;DJ-1T7454&;2=6B!9HKB-GZ<K)]Y=V2%Z?[/Q?U58SE7*Y-<WV>VJOS
M6;V:;[[:'S?^MG#W^L3X1>9Q6>*DJOL'I-Q:O=/9M6=U:ZL]+)M>W4445S'T
MAE-;*L@<$<0^2B=R",$\ \<D^Q]J: 49U482*$J#ZD_>P>_S$D>WUKX]_:?_
M &K-(^!=L-#T"'3_ !#\0[F)+S^RIY72ST33CRVL:TZ%6A@0 !=C"1VSRBK^
M\[?XJ?&?6O _[/TOQ8TK3=/N]:_X1SPOJ\6EW<CBP:;7)-)2>,NI# 1_VF0I
M)S@ ;B0"?0C@,=)95>DK9T^6BYRLI62CSI:M1;<HQ;NY+FFE:U_@L5Q_P?A<
M7Q?A'FWO\!89<3<6*,>;ZM2E&=1<SNDVHP;:5DFDK_$U]*^=_P!,G_[[2CSO
M^F3_ /?:5^+W_#Q+XN?]"E\/_P#RL_\ Q5:>E_\ !1/XCK>P#4_ _@J]LC_Q
M]06-WJMAJJ=\JL\<T?7(YC(]17L?ZJ9O_P ^5_X$OUB?FZ^DSX6]<RXH7G_J
MGBW;[M?N/T>^-?Q\^$'[./A$^/OC#XVT/P)X=^V6^CV^IZU-Y*W>H.A9--T]
M$5I)9Y/*V+&%VDJ=S( &K^23_@J%^V_\./BM^V=\"O&_P8^-=YJWA'P/IG@A
M_#^J>&;S6-.&B^*&\;LFM2:.WEQ[Y7A6+SF*D[LH&945C_0#\2?#/[,__!3W
MX9:;\+?'C>)/#GB'P[JX\8:9IMEJO]E>(]!U.""30X]?TMU%QHGB'0W76A#N
M"W$<K[%"0,_S?BS^TA_P2)_9S^$OQ^\"Z;9>*/BAXBL/LGAG66LM5O\ 1)!>
MLFNLC+N3PWM."N#CH<J>017TO!.&R;"XZV<J:SF,904'%>RDE97^%WT;Y%)I
MN,I^Z[NW)XH<>+$<'?ZSY,J7$/!,ZG"=12@VY-3JN3;NU)?8NN6-I:^;_IA\
M*?M,_ CQ1*;+3?B9X9DO;>PBO+I;N,::4CD=(P -6CBE;]XW"@N<<ECV*\H\
M+?L"?!/0[FXN]4;Q/XH$]M';6UMJ%\WV:PCC=7)MT3G<Q&W<6QMW#!)X*^1J
MOA_G=JV+2_NPI-==N9)_A;16;U9]+A,=XXO#TW4R#@1SMJWQ7Q;?RVH]OU/E
MW_@AS_R81X:_[*;\4?\ U,9J_9).A^O]!7XV_P#!#G_DPCPU_P!E-^*/_J8S
M5^R2=#]?Z"L>)?\ DI,W_P"PB7YH_0N"_P#DD\D_Z\_^W'Q=^U1^S?X^_: B
M\(V_@+]ICXO?LXOX:U;4KO4;CX47%K$_B:/4HH]D6KB<QEU@=7EBVG*-(Q7;
MUKXB_P""=$OQ;\3#]OCX(_$#X_\ Q5^(&I?#SXL:E\(?"'Q,\5ZTE]XIT%7\
M':S"NN:(O']BZ\LDL/B;RSN E:!N-JLO[.VQ$D8DQ@F.&0?[WDL"1W/('.2.
M37Y!_P#!,[_DX#_@IHO3_C+%F_[YTC61_P"S8J\+63RS-H-)^S]A9M)RC+VT
MKN,FG**M!*T913NVU=W?-CZ&%CQ!E&*?-S9[4Q$)>]*SY.%JB5DY6V2>B6NN
MKLU\3_%']B'XR:!^V?\ LE_#6^_;S_:6\2>(_'/A3XYWFA_%;6+WP^WC7X=_
MV!X*@?5M+\.,-T3+XN)C/BTG:2R1$>62I7[;_P"';'[0^=O_  ]+_;#\S9D1
M"^T#S/\ = SCU. V?]G-=W^T"?\ C9I_P3^Y+'_A!/VGQYWR9E/_  @D/[T<
M[>,XR23\G)S7Z=$$-]T_<.+W,1Q[<<9Z G?NSW_AKKQ^;9C.CED92@U##1Y?
MW.'^'VM9<UW1NXJUO9IO:\:?.YM\&6</93]9SB7)-M\53JV5;BA6DH4I*+<Z
MJC)WD[RA>EIK+9'YF:S\0O#_ /P3/_9ZU67XZ_'KXK?M.^+/%'C'4I_AUIOC
MA+?5?B7XUUW6+'0M(T3X8^!M&CD='TN&]B$JX5XX)];GDG9W>.-_)=,TO_@K
MO^T?8-XK_P"$W^#O[$OAG4$^V>'?!9\&M\3_ (G:?U!7QK_;RGPLKG;EH+=1
M@D'RQN7/F%A\2/@Q\4O^"I7QF\=_'7XE>!?#W@S]C_PUX6^&7P6TSQKXTT;P
MS967Q)\2JVN^.M9@TS6IK<ZMXC0,@CN(2\D,,?ACR5,PCD7]4H_VN_V68LJO
M[1_P(2, X/\ PM?P4[M@^VOXR1[ ?C2KK%86/NY8JF:3C[9SJTW)2A4C"=)4
MJ<:?):49J4GR2E>5VDW=%)X',5KFT\BR?(9<G[KBQ)M1TYJTG)<L5;EBIS>B
MUVL?GKX@^*?_  4O_8ULV\7?&[1/ '[8_P #]&M(I/%_BOX5Z&W@3XQ>%],A
M5GU?6!X'.SPWXD2,+YK1V\L<B!3N:,.^_P#3OX*_&OX;?M _#?PW\5?A1X@M
M?$?@OQ59?;K&[MMI>W 1/,TO5(%F,FD:Q \H6:VGP\94DB1)(6?C#^UU^RE*
MA2?]I3X&['!WQ2_%?P3D''R\C7B>N/XLCD'I7YB_L+^+OAW\+?\ @H-^T]\
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M*7Q&O[&RFNO#NNQ6(M.5:^\-^+=*.&76\-LDUQP<$<+)&XS\K@8[KX ?L_\
MB[]HOQ;J?BWQ9J%\OA$:J^H>+?%=\Q74=>U- N[2-';:Q2"/>OG3;2(PRC!=
MD1\X<.Y7A,7'.<7.;R-2O!QD^9IM-1;6]FDHN+3DE%2NXW?IKQSXZXIR=\!9
M-PDUXITZO^JO%W,XQIX6:IM3K4Y*W(I+FG)MJ-/WI1:3T^5]6O\ 4M;O;W6=
M9O)]0U74;I;JYU.X4#4;W45 "JJCA54 !5 X  & ./VG_:#_ .3(HAZ>!_AR
M3]3/H&/T6OSL_;$\'Z!X)^,FL>'/#6BZ9H^E6OA+PZ+2VLUV#C2Y H"Y/W4
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=E3X3HJ/*Z,7=Q4'!1AHW:*M?<Z^BBBOES^@C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>lfmd-20230620.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauBebP9z5Z8aekhvWBzbamKDyEoChdWNCADeWWW4QMD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:LFMD="http://lifemd.com/20230620" elementFormDefault="qualified" targetNamespace="http://lifemd.com/20230620">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://lifemd.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="lfmd-20230620_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lfmd-20230620_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lfmd-20230620_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="LFMD_CommonStockParValue0.01PerShareMember" name="CommonStockParValue0.01PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" name="SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>lfmd-20230620_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lifemd.com/role/Cover" xlink:href="lfmd-20230620.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lifemd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20230620.xsd#LFMD_CommonStockParValue0.01PerShareMember" xlink:label="loc_LFMDCommonStockParValue0.01PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDCommonStockParValue0.01PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20230620.xsd#LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:label="loc_LFMDSeriesCumulativePerpetualPreferredStock0.0001PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDSeriesCumulativePerpetualPreferredStock0.0001PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>lfmd-20230620_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lfmd-20230620.xsd#LFMD_CommonStockParValue0.01PerShareMember" xlink:label="LFMD_CommonStockParValue0.01PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LFMD_CommonStockParValue0.01PerShareMember" xlink:to="LFMD_CommonStockParValue0.01PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LFMD_CommonStockParValue0.01PerShareMember_lbl" xml:lang="en-US">Common Stock, par value $0.01 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="lfmd-20230620.xsd#LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:label="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:to="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember_lbl" xml:lang="en-US">Series A Cumulative Perpetual Preferred Stock, $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>lfmd-20230620_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lifemd.com/role/Cover" xlink:href="lfmd-20230620.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lifemd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20230620.xsd#LFMD_CommonStockParValue0.01PerShareMember" xlink:label="loc_LFMDCommonStockParValue0.01PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDCommonStockParValue0.01PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lfmd-20230620.xsd#LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:label="loc_LFMDSeriesCumulativePerpetualPreferredStock0.0001PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LFMDSeriesCumulativePerpetualPreferredStock0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140558280598000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 20,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIFEMD,
INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000948320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0238453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">236
Fifth Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New
York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">351-5907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember', window );">Common Stock, par value $0.01 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LFMD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember', window );">Series A Cumulative Perpetual Preferred Stock, $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementLineItems', window );"><strong>Statement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Series
    A Cumulative Perpetual Preferred Stock, $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LFMDP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LFMD_CommonStockParValue0.01PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LFMD="http://lifemd.com/20230620"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lfmd-20230620.xsd" xlink:type="simple"/>
    <context id="From2023-06-20to2023-06-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="From2023-06-202023-06-20_custom_CommonStockParValue0.01PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:CommonStockParValue0.01PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="From2023-06-202023-06-20_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000948320</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LFMD:SeriesCumulativePerpetualPreferredStock0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-06-20to2023-06-20">0000948320</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-06-20to2023-06-20">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-06-20to2023-06-20">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-06-20to2023-06-20">2023-06-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-06-20to2023-06-20">LIFEMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-06-20to2023-06-20">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-06-20to2023-06-20">001-39785</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-06-20to2023-06-20">76-0238453</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-06-20to2023-06-20">236 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-06-20to2023-06-20">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-06-20to2023-06-20">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-06-20to2023-06-20">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-06-20to2023-06-20">10001</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-06-20to2023-06-20">(866)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-06-20to2023-06-20">351-5907</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-06-20to2023-06-20">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-06-20to2023-06-20">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-06-20to2023-06-20">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-06-20to2023-06-20">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-06-202023-06-20_custom_CommonStockParValue0.01PerShareMember">Common     Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-06-202023-06-20_custom_CommonStockParValue0.01PerShareMember">LFMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-06-202023-06-20_custom_CommonStockParValue0.01PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2023-06-202023-06-20_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">Series     A Cumulative Perpetual Preferred Stock, $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-06-202023-06-20_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">LFMDP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-06-202023-06-20_custom_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-06-20to2023-06-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #"(UE8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  PB-96%FXZHNX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TUAD=#M1?&D(+B@> N3V=U@TX1DI-VWMZV[740?P&-F_GSS
M#4R#46-(])Q"I,2.\LWHNSYKC%MQ9(X:(..1O,GEE.BGYCXD;WAZI@-$@Q_F
M0*"DW( G-M:P@1E8Q)4HVL:BQD2&0SKC+:[X^)FZ!681J"-//6>HR@I$.T^,
MI[%KX J884S)Y^\"V96X5/_$+AT0Y^28W9H:AJ$<ZB4W[5#!V]/CR[)NX?K,
MID>:?F6G^11I*RZ37^N[^]V#:)54=2$WA5([56E9:77[/KO^\+L*^V#=WOUC
MXXM@V\"ONVB_ %!+ P04    "  PB-96F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #"(UE; 'J7)\P0  .X5   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MK9AK<^(V%(:_YU=HW$YG=R:);UQ38(8ET-)-6!IH=[:=?A"V $ULRY5E2/Y]
MCPS8)#7';";,)%BV]?)8Y^@]LCI;(1^3-6.*/(5!E'2-M5+QC6DFWIJ%-+D6
M,8O@RE+(D"IHRI69Q))1/^L4!J9C60TSI#PR>IWLW%3V.B)5 8_85)(D#4,J
MGS^Q0&R[AFT<3CSPU5KI$V:O$],5FS'U1SR5T#)S%9^'+$JXB(ADRZ[1MV\^
MN8[ND-WQ)V?;Y.B8Z$=9"/&H&V._:UB:B 7,4UJ"PM>&#5@0:"7@^'<O:N2_
MJ3L>'Q_41]G#P\,L:,(&(OC*?;7N&BV#^&Q)TT ]B.VO;/] =:WGB2#)_I/M
M[MY&W2!>FB@1[CL#0<BCW3=]V@_$<8?VB0[.OD,V$.;NAS+*6ZIHKR/%EDA]
M-ZCI@^Q1L]X QR,=E9F2<)5#/]4;B V3'5.!E#YA>OMNGW;=G!/=?DNC:^)8
ME_#GN"^[FT"08S@YAI/IN2?T9HHJ!L%6Y.\[N$3&T$K^*>/:Z=3*=70.WR0Q
M]5C7@"1-F-PPH_?3#W;#^AFA='-*%U/OW0HOS2#GSS$K@\.[MZX^(Q"U'**&
MJO2!P,\H1@%=E5'@_9<T2!C"4<\YZN<-QI1)+GPRC'P"*5@Z+KA2GDQ5V=3(
MT1JHX#!27#V3$0\8F:3AHCS#<0W+LJ_<=K-51WB:.4_S')X'MN*)DA3&;$+#
MTH'"=>[&H^'][>7%>#*X1K!:.5;K'*P!!%'2@(PCGSV1S^RY# Q7LN#3KK5<
MQT*PVCE6^QRL.7TB8Q_8^))[-+/PT['$%9N-*TBL5JV.)9=M%99IG0,XCCPA
M8R$SMDN261@1D@Q$"@,*XRK\TAA7J-\.,<@C7[?/@>S[/OA@<GDX()F]?HG*
MR7!)QVU<C/A2K4E_PZ(4,Q&[,'X;=6R<<[X5I9RXY"SE$(F:A26C77B^C;OV
M:\"!;D&8YV(;E<+A<A.VO?@&"Q6,K2@%-N[EK]GR')Q*L>&15QYE7'/R#4,K
MJH.-F_IKM*E(%)C,7SP^/3%P11M,QL;8BO)@X]Z>A; /B]C3*+C AU:C\1%#
M*2J#76'IPH-1F:Y%A)6J"A&W;E_5VU83(RJ*@HU[^5?)E6(1#$T8IM'>>I-2
M*ERH:J%A%P7!QOU[)@+N<<6C%;F'!)><!J4\N$H5CU,4  >WZ*ED5QX,#X,9
MMEL/PI*,2?)EN2R/7X5>)5GA^@YNT?\C&R=)"F25@+AL)>#1.O\LNQ^&3*YT
M/'\!!2@HD&PQC4I7'A6"E6B%T3NX,^N$AT7&3 GO\9+$5)(-#5)&?K2N+9O$
M,'S)FLI2N\"5W_A6XA1EP*F]U]L3ZOUO!2V*@H-;^)PK6)*+);&=#XN/9,:\
M%-RF/.RXTBY8%P0^WQ>PE^1%R7!PQY]+ZNM\G3V'"U'J/A4"=Z/[6XRDJ!@.
M;O:'02/#)V]-HQ4[^3)1(33ISV[[OV-,1<UP<*N?@2>SA/3)( W3@.J-%OU:
M&#.5ZNHF&=B.9/XA5#I 5N6<0G_RK:E:U!RG_5YS"BT[;]V2*(J1BQ>/[YA3
M%4J[*&9SZITB^?*1BBKFXN6F>K)5".C)-L50BGKE5KQ+G#W;*H1.SS;S:/=.
M[X3>4UT:$Q*P)2A9UTUP0KG;7-PUE(BS#;V%4$J$V>&:4:CO^@:XOA1"'1IZ
MCS#?XNW]!U!+ P04    "  PB-96GZ ;\+$"  #B#   #0   'AL+W-T>6QE
M<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/ZZZ>S
M;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N6/O.
M-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NC
MSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K <
MXRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=J?$,
M:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'
MR6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D
M$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(
MT5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C
M_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O[
M"_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[7FY'
MU=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..VBB(K
MU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;
MK?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX
M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  PB-96EXJ[',     3 @
M"P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%
MBD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L
M'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+
M,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO
M8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( #"(UE:JQ"(6
M,P$  "("   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>
M0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!Z)1\>1=B;FJ1
M9IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$
M*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.
MY68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B?
M:ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G6
M0VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_
M,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    "  PB-96)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ ,(C65F60>9(9 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( #"(UE86;CJB[@   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ ,(C65JK$(A8S 0  (@(   \
M     ( !^Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #"(UE8D'INB
MK0   /@!   :              "  5L2  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( #"(UE9ED'F2&0$  ,\#   3
M  "  4 3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  (H4
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lifemd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex10-3.htm</File>
    <File>ex10-4.htm</File>
    <File>ex99-1.htm</File>
    <File>lfmd-20230620.xsd</File>
    <File>lfmd-20230620_def.xml</File>
    <File>lfmd-20230620_lab.xml</File>
    <File>lfmd-20230620_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>19
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 26
   },
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "lfmd-20230620_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lfmd-20230620_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lfmd-20230620_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lfmd-20230620.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 65,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 2,
   "memberStandard": 0,
   "nsprefix": "LFMD",
   "nsuri": "http://lifemd.com/20230620",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-06-20to2023-06-20",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://lifemd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-06-20to2023-06-20",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "LFMD_CommonStockParValue0.01PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, par value $0.01 per share"
       }
      }
     },
     "localname": "CommonStockParValue0.01PerShareMember",
     "nsuri": "http://lifemd.com/20230620",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "LFMD_SeriesCumulativePerpetualPreferredStock0.0001PerShareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Cumulative Perpetual Preferred Stock, $0.0001 per share"
       }
      }
     },
     "localname": "SeriesCumulativePerpetualPreferredStock0.0001PerShareMember",
     "nsuri": "http://lifemd.com/20230620",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://lifemd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001493152-23-022145-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-022145-xbrl.zip
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M\,TV6YA(25VVR-,:'"TP;SK8&9T0?!,7@54.VFI@O]1XJN'SL%HS?"1^MIZ
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MFK#(14%TY,T38I%1A'7+^HSA4IR,+RJZ*T3GE>SU:T:\KF8%+AB&J4!#9,7
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M%J!3Q2W>U0CB8'<GT$Z\N;@S\=T IVX!RH6L$^N.>VDZ!->VB'/WA";PUCD
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M@-3TA)3[^#/2I'+SAKI!.FJ-^(6,_O 7@WR&ACA/I\@7B=FLO4L81^'RP"P
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MQE]D1A?\;W():]N4*J'#Q..0TT2^7Y=]-%K?P;<H,K!0D?%B64LSF,N.V_8
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M-:&PKY5S.K[>T-UML?&\WLY5L;TH1B?RB"Z*(T=;11*N3KB6]H\E3 BBHN?
MY[T*H0NIK7%B34\V45ZT/E78FKQ.RJ?-TZ$"R@F2"EX2Z9,-SO%TDGKHFI,B
M3D0/VIW\XL< -- IU1"*&I$+R4<'6AXF6^Z]+LIEBXLS?V,$MQ[Q@K4PY7;F
M(!WXOA%S^1-''84DU15%HFK+M99GJU8*UKCHGO%*:WR-*:,?"[XEVGZ)K4MP
M&+FPS'E)(*WT'MMDLH@1V&7I:%&#\SKE(T9).L:228NK ][#7)?&=?+>)LSV
MTP2I#);9*DI+V4IB$E#/H$E0*<M8(M:K68\E@Q+QI*@3/)0(_\7G&KR&[XWI
MOF/>#9X7)\L&Q42#8XMP[Y6+8'D1*R(8Y$@8'S',W,F21O-@&T22E6.GF2_L
ML7-E,["<>>15$D 4#,N(*0?F#1.DKPO.;4H1ZVJ@@'Q*AGM=GI6@@F-P1,F*
MK/B&]\ZI:!K9,NEC<@G2=K!5AH!5PDH,_M^YL1K4N9X^XVHJ2TN$G6+O<:<%
MML$=")&[K\"O50X(Y&D&$CO&H$D21*-P0CI27!_F?5+W34_00%IA6U/OY/K+
M-@# C>_R'];X G<?+_7I!O@ EUU/??::=??:VN2]\(LZK20Q!+B*K0N&=^\P
M3B!WP"93_G;Y]0YO"\IV52#;7[9 MFL%LCW: MFVWL85)_)X/"R%MLR1P/&S
M,O(^_HC9NB%"-8Q,^4EG+X*3$_>4W-QQB".UIM6XB99ZQFEXO?HV=1*8U&14
M!@;J[[*=0X,Y66<O7^I>[>X<QP6+Z\%Z8Y827WF7,XY$QBV:WH. 0VQ:^<LK
MQEA@'T16A"0M$")A?;&1XHVZ\3XIH70;#<,:BNC;^((1UFRXJ2^$J5]BBRY2
MZ?-1CT4&+4@-/0J$'H&V]\>?.]*QEK.+?N\6K4IU<#[7F<Z2(*RM-AB-/<(9
M8/YAM*<0)>0SLN06OQ@<HA%CA>1Z$"\-S66[HR1J.FY=A-2B C&*QJTW4H:K
MQ'@C2PT@M4,6+B6F:.C5A?:U6P3M!ZCQ5] NX%J74A%K,BH?X.8GBCOP@V)V
MN<B!]Y>LCH.RG[(XZ:>LSK :J3%=WU3KG$$_]A#RF!.+1J,M4#"*L2_F<F-0
MH# C!2H(VW:M=Q%=()9"B&N=PFVD\ Y-Y G=W3]A]3?BQ%2D5A(CC.O%K%Q?
M2>>.^3&1[J;+#=M]$DA3A-!&"(<):$(P:VDL1_4[I$67X$NG,;BAC5"AQH-?
MRQ%7@R&ZGRB8KZ/0:JDU=;>Z&%N!OD,3^98%&I/R.96<XZZ^K3LK@2S9IS5<
M']+=]?)DSP"W->K_.QBD)[#IR-W5]A/*QT2AG^2BP8Q,92U$DC\T?#VL&GQL
MTB#Z@7D<B7 >S E;N0^?Q,)BK0W \@>_F;,;S+ZS2*\\&=0(:5PJR2&PJ8&Q
M))&-&Y[#N=]#VF/=P(%<;N$X*XMWB$\DW8_H"-K(Z94G0YV<:FJQ@*%1K^OU
MF/HX0[PVZ+H%S%+W"?10,34;8T+C;Y:=]Y <-$]8 2+E'._^)!(]Z,(4/$?M
M0 ;8A%/HG,E*;2A9*V)<EJIT&VXQP=Z!@^\R8D6,&!ZD!+;3S?'!JZ?'%5HT
MG#J'G9E(VF;H-TQ1&[R$T6U$1"U=';)LFT1@79)Y9#O2L$DB83JEA+]<N<V1
M1ZWT_AE0J^%(M3P^RJ0P5@&>AL.:107":[-HY#2-2):#!C068.3=MAHN=0?,
MH;XX,Y]NJF4*#T9>P-$E<%4GU&=(WMAL#I*.#]L#IOBE4_0473>.^I*4@/3/
M3-'):I*#XBV9W[Y*>AC"M)2W+3"P57ULK_ [-)'OZ I_)3Y59BW"]YI$C4)-
M=*-OD6IW:RH8Z#FM67_[1WI#G2:<=KR,9GVID"_M!NJQ*^+Q]QJ3KLOV"R!I
M8,HS!C]Z -65$CLBETMUVL_@D@H!\'^Q32^H&?WKLC%4>CGBG5-^VQJ;7C/3
MX3WYNZIYUVK<L5M5\U$/I:QU#%N0!"<P:';F(=.^VYOL[SNZ1C3\P,3;XL_O
MVE0PXCAV'AT65%NQNYV%(\Q(3,\R(B#T.!" ;NSH3%.@"(.*%"K",/6,@E%8
ML.Q+E\J-Q,^(+/N*R#-;!CZ(TJ'#P4":PN2QB3>&OP<A'P?IKST6<4=#=Q)H
M"E[C&T)78K^+Y*5ML"A<+AJ^0ULJZ);!ULJ&[T3--3 X,JY@7:;#[OJE<R-@
MP8"VG#QCQQF5)GM'^]S*P7: T.X0!#'W&3Y=5XTT =NTPKE1/(999!)8RJ9?
MA!0VNSM[+_:U<\*ZQR6M4@>G:\:2.1H<$IXUSW%T,^%S=G?L@V!)UTX*0_LO
M:;1TA]#QJ>J-0W=[''?06/.%W9UPLB.%I*3SK9M:+XN*BFOS'%O].8='.8*L
M>R3L!(Y[U_.0G%R)TT[@UT\03L_M"T',OUM Z4H="*C'9R;=D3_/(D7 V2WI
MT#JLQN&#+5CC6L$:C[=@C:TM^(F-#DYFJ,'WQ]R4J^'0@G*84?_%5\J^42F,
M?)6C!G ^_J56'$7*-U? \?"L>8B\'%0669HSX?P06W.\3M+STL8*)3]A!49I
M1BW=AY\UIN KT4CJHM%MXCM9CD_R,HO6NR^]%'H4*,U65T>NN/8EF,"EDIZ]
MW[CPI?(R*URA%:9*UJ&&AQEGEV4;\61Y/6$DC8<M%E?XDB^!#8:]T9"?%-WD
MRS[-7C5C:/)D;\73-%E3%IB2P2F"H%9^>MOMP!2,"3AS\&<![+"O'%C+* U6
M+,A &09"=(=3#U<.0LL$+O1.^MVZ# Y/Y;*B("PN)MMSL2Q7SNJRV%S]M.!9
MM!O'III1V*$W<-JHCT=+X (!#.F96XS%@1;&=%>0Y81YNABOXN)!]C1/5AX;
M;/>?:G]=:Z\&O"2R*]CA11LY\"FYHG/IP\#D1F2HKS'%QZ^*R3X=&0M BK]E
M+RQ+ 2IY%VF6U\1>GV_/5_FZ+%^4W@O4)'8".^=(W)S5V-S5.!:Y$LPZQ3<8
M<VU'2_B*W[>\W"^O=CKC]RZOK._X4,>6-\CPH1LX,"#6K&&0ZM8U++K?OW:5
M4A$145TPD)#>EBLEK6[!I5JMO^ZD]HDRVL0#-9+MM>UO;'&I-'P39]"60 O,
MT'F9@T:3]EG/3IX_33".M*[;)'W</8!18+8''J?L)&Z.5".X-U:I7[*:25X;
M*4.CJX=/D=QFV3#A[%KLX')<2FA%26W7=76^[XZ?FX] (^RKZ.+@MA1]F37<
M1@ZSJ QGG61MX7+"O K8\B<YFK0$5%,Z07H395CAT.C;6.BE6:2_$#P*I"_/
MVK%5HS-+KQQN:='*.X4A4?*Z' C$:AV;ET3[@LWOJVP.[C3M#9$;CX\K\8@H
MP3(HREA<8'"XHGF3752J&?L&3 A"9420S_'OHKU%&1G7G9!-P.J>?!9."[.K
MT0G#$D',WBRE.1_-ARP:,+ :U&WGP>0MT1\]?X,:D<)+>I-5)3QF[R]K%,N:
MEWLKO[O36B9J2]DY5;J ,%A.\(0+<),68+P7#*!E9X*;B3&//N_+)J)]D;OE
MDO/NW"76Z_GK5 XG;' Y^/[P]-IP>/:5A2TKWSS2D8%@3@X6"\G_W<K9\1 F
M"'VYL;74,E%7;.YB^A;0/UA1KT7S=VB%$ WA1Q/$!(.H?7A;#JQI/4>B\1\]
M@,TL#3[&5_C^_82RUY+P,O% J0(8!L(1758T;>?U2Q@;?TB/=]5G8Z%?C5IC
MT[,5&+R[$R"#+^7HPP\N35>H \;*8$..9<8)Q[H,FG$Z%4&'1/%M;NW5*%D_
M$O](NPX<?G^Y,<$2&+TB-OU^R5D[;BQ2#D X%/&K1;,(#!MFC"=.VKJQOQ"%
MPE]3RI&7 7.M) S<G<:?)A.-WA(3"5W,$84#W[7+UU*BH*UYB<\Y(. >Y<9;
M.VI\(KK=?%.AIBUW=S#3TK5CH#:"S)>VS_9X(?Z@"=8F$\T6D0S+1EP)\<!*
MD&T/4X+KC-9M:OE.H77^3&B=ES4:/@Z.,^(73.4C1@^$E3#)_0QXN-:4'JVK
MO0VY]_308(;HHS40+G6V?*@M6^(2_Z"OB\48%F@1IL2!;J7.F.WI98-DE;:_
MD@M;P+,[UCWD0WBMD+AIM#S#X[)=@^.-R;@=HI.X5XFO:1"%TPIIPKQ\-.OH
M):*;U965X"$G,#*57WE5:-@0+]HWBN_A5T< FR[6.E*Z-T8Z='.5>URL/>H1
M7DOEWDBKP)$:/HHOC!3QC7S;Z]'W1]L:[GL$$8$TX?ZLJPIL:WNDR4U6,*R>
M$6UJN"D&_$E'<UOY/II-/=QF4Z\UF_IDFTV]8Z?@VFR5OTAQD&G[Q=+F'(\Y
MW8EZFXN#(BKWC61/1:5*[$IW:!!X\K1?C(?3<@8<J1ED3*X$;/-IHKX"._.K
M,9@/'Y 4OJUW=]Z14'GRR/+WNM[<AE!K8E18Q!N7)JXKRZ*.UDZ.\6/'>NY8
MU)627(PZ+&U!KQ8$"60\*_>EDO^\D( IEL]3[YED69H,WUG5)75EIY0B]_#$
ML 9F*LXQP-*E[*.B'3RE-@T4E;63'8BU+2BAC&"4Z1\[6N0E8XAI+4@A2!62
M0:ZAJ.V9N$,3.3R4,U'=._X-K-J66L"*)XE>@[2)6(?$(#F;<.^)J ,H*V[Y
M?A0"HT"5"TF.\CVD$HOA<"S%[\\O022GWHOQ?#32(-5)XAZ:1^@?G9MRE8:8
MXW<! &8%ZD'#HS'8V".'BY-%B-T>*:CR<V1V,'X/$ Q^TE%M+J-#Q8]&0]W=
ML6,-ZA]H=]1Y%-X%9= .&J@RO@6=@7 0=J,%E3$9G1P1=!,4E4@9*/8H0K!V
M3<739JW07FW^!%:F-UHRB=&BX8Q)7RAAYKB+AROS:4L0>M&2&W+U*1S,)?K<
M\+0@7UU>+T6O(F^LENA[;2C&&4]HH2T;#Z\8"\W$<)0!DZPY4J,7[3SE_JKP
MY4D Y-(PW^[.)Q'M;O7T'9K((5.0O]'R40SS:2TEGLS7/5G,SHPAX>^;$1R=
M%^R7%LU^\^$12GX*IP1] + [5YTS.R7Q?ML"Y]3'><G'/,2VS78.^0A1"X '
M;"@BUQC64;U&^PM,15+I G$QNMH%S 'N/=S?W:&67F.Q=H_YWR?I<67MEL('
MICY6)G\U'B -6:(]YY7&VP=JZD0?-F"MU)Q=4/C,3>X;VT6'6*0I-B6\&W6D
M$,.%=4=?^Y]?QV0/DI^75#H4!Y)'4QU2&>Y#>12]TT@#!DYA"&)-X?Z4Y/F]
MV^$U:D1233R5*!TZ>P2,3,M,P'.@H4$KU\()%+09T@;3VLBMU>S.]4@-4V'8
M;;/5U*-5C-*&C7MB<Z%\;ELN8Q5+59E&BK*&J\ZI37B"FF0X1FFHS>7V'@TR
MV%SX25=SV3*6IS%2TNC*-.)6UH' .VE?8'QZEIW7#07+=?B:[J/57%VMF9MW
M!:>>BA":5@^PE3KOAQJ$$VLP=K#,"*<BQ/ KCZT)?:U6<0[4!,:O1>5(]:!=
M%6BC3M"Y\#XP@HFBU= ,.9GHJ-1XKY0<N%4P49 [4"@083ALBXG6O[=73%"F
M 74;FA[4B[G;/+!>Z+ZG1>9MRJ8?J_JB-#FVU++@):U\HE$VE&\5)@.2?R:@
M:H5L-5#GQ&Z&_ &MQ[. >%='"<?BH[P8JIA1GI=EAG6\PGS!#2-RRQC0;NV2
M.S210V:\_]!/FMIKA8+F"5NOYR+X>@;&6SH,KPUNG4,/-3%%A24DD6>B*>V2
MZ:JR6<V1)V 9_T(W5G-;?-PY-M@&73G'K"8&YH""VP_8@2IIQ\L4FJA1E@W#
MI&>F:6R/W@$8:0.H+\K;:)?* -,WVQ_I*&#YK@EJ@%B&(+7D8UH-7A.$/Z)$
M&U\->[*<(],?X9#WEV%30LQFOZ1W7RJLXAQ)!9.O'B;FB [;,A\QHBURKQRU
M>FC[W!)>8:LHQA7%8QM\?>5Z N!6_L2GN+UM-I&OHG8 R3]\5I[ -)(V[*,Q
M$\7Z$7F'TZMAYGEC\WBIXPE4=8!&P>2)"WYE)>B*?.42X S\QDHL>?U>94+Z
MV348)XMSV/<B9!%#ZRK5SD=C<1942NNC?U$$T2D[R^JT4?$GOMYG\/'U*/[]
M:$O6UU;Y)"X!&.66R>V_HH,WV1_Z+B :7 <F9X)#TLV*_I'%A"Z'CXGW@ROG
M?8,(-PDY$08V^EA0?8HM+% N^"8?J:H,VFN@W!A[CTN((HYJR#U<,54/.&,)
M6G7HW4RS)?A!);=CX5$+ESAAP2MRNF']LC-:$.X%W[K&P;PD=2EX2QLDH<@3
MN(YE(=XW/(''JP @!PY:,Q8R-&0QZEDB=$;PT@*Q/OKL-LX(X!3D)')R "-K
M=J7!ZM,D@!S*_="QTKU"O=IJCNQR,)W PE+F*J$P$$'&[6MQ"@QY1J1J \H1
MAE8<8+'=R?-TS%7T[=P&=[)8H.@I7L]]6K71Z]ZO*JJ9;7#@8;+GIN&%.(ZL
MN&"*'OC?\9I-K^,[)R0N0:]AG/NI\EQTSB'P[5:+)9MSOT,-B'GRO/9%E1>3
ME#M1!QX]BI!RSL[UNF3;]MBV8;:+R@FU>]#U.G)AM"3: ?3IZUZ]F1BS2L&(
MUU>8Y CKZ*R!/G[#[=7C].L3TUV8J% YY O9=RD.INHF1X8Z5*U/[?FM"N,#
ME#*6D.MP4=9AB\[K*86%+C($Z:?$H5C!0K1S75GX#<8!VC6B:J]BB]L3RLL-
M ]&6OEU33'HIE7%^;!*LF.]!XF\_%MQS1JY?RW,6:@.;<O/4016V=^-&3'ZG
MM\$P [+/((<UZ).[NT/SIID-F),)O%+WF (:G%LMIPOMQHP#Y&'5B K>8)RN
M!@&+5SG7Q.P =H55OU_%NU^S2I&S;]/3XSX^C&38-3/<I(@>A_;*Q< &LT0U
M!1JFX0Q$T>12]<2AU&F1-85#ZD>GU[OJ/Q><_@MU1J]SV/& -V$Z'VXQG=>*
MZ?QVB^G\8L_@#0>$G@C;+#&"<EDAW=EA+^W.[YJMI8HCO-M_) U'A0V8=0N[
M(X_2\G!A=+$4QA5QXZ_ BHKW5DN@4C2'398'WQ7S0>JU-"/J59?8OJ1U8PFB
MW:WEM5=AGR,P%&S>'6TI2K<@4*4O.U==8I.P7F6>'[SQT4WPYIZGJU^:SNO6
M#%I,<',8N"CQVO;M%D*PZ!^T_,]+ 5=:$$=D-4(43Q3@,]CLCON"XILX(4I;
M(BSFVFUE;!/VPF@]I:.RW#U@7^+8!A1ZE- *;824LV\CA5;R?;4>&JT,#9QG
MLOTM07987N1Q6S"TJD% Q(Q:2G9LIC&3KJ+MA/$ F7:"!P70 N2=LDMC]R33
MOB#A%BB^"&N4<39^[? ( 12=/)"^&58K8\,QVBA"B79(@02/P7%1]A;I=_(!
M)Y.F7UL]4%,],_3B<L58;=8'EBGX$Q<'J7N#-(_:A5042JM%;[4D481BPRTC
M.]8[B1/V;*==0)HJA$]C:7M5'S2:QE!$HC6(ZNB,7?8][:]"(D+))Y09Y-"B
M"M1EV;>LI[RZ\Q+<IM(^8AB@=2P.XU5H!.PI;1NWSO I&DG[3(L&7$G<\RE5
M+07VM/V4>-YC#0+"$'1$[3(:D9YI'&B]3RW3[.:4YA<^KZ54/XVI $;\>-U:
M1[$RW&);*1 $U+=F4B$ </2;$1T7:5.!'M&C-LR'H#*;)A3T>_*#]2W#R"W
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M9*6@MN.-]&G0KJU M72!,# #YL!>"Y%U-C.)I=U-%X2S%F0B[\=I7H*W@7+
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M/CBO@CCB5'?S6YG5:U$WFPRG=J1V\JT6?9,"0_UG\H(4@9L1&.H_E!?02&Y
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MZ89Z?!%*,B9EX/$IJD9L6D57HR!@F<R@OMQ=@-)@9EU0U+V)M'(3J9L-5%'
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M0Z_,0\"$V'_.FQ<V R.X!3]:4)/2#)(@MZ54WQ[#!.<(5K&=6&O\;SC)#)M
MB"-N'OK6T_@J:5RJ[<\1<WHBIFH7C>-Y49F/AI,C">7<;ZH=B)Z@?*Y;W7LL
MX 0TUH+7LAMM6^((4U:E9MI"J8K0'\==8UW.$<)Y"PBBJ-#>U1%FTQ%40T50
M&:X'?W6%!W5SLCO&P]4AIS6.6+/H7G &L,^Q/>RD+J%KR()4RBB<9I$;+*J'
MX;_1*)@K,-@CDA7<V(0!\+:W/QX.)!E\:B)9 _?K]'V[UQ9CNG(/<:4,;*Y
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M)Z_.CW]%:??DS>5/;U_^/U!+ P04    "  PB-96/&!/F=HN  "#4 $ "@
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MM,Q@_0!ODOFT>/=]/O<BJ/7U%@:""ELD.%*$=#WKXUEO,YXU; 56</)*Z5=
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M!L=^"'K1I!6M$6'BT:!Y:=Q.O*FD$]081<%^&*#A6+=S ?UDAKM #F-50E2
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MLOF#L-*E^L5S]*\W<J<N]R4XL.U?WA_^A6/=_O7LW=M7_PM02P,$%     @
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M.L'<H6CZB&W ?^7NT#?B_%?DZ)MT_P902P,$%     @ ,(C65H.X(U\!&P
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MU*Q;.AM\9L.K#/S;+>SDG];N[EB[99!='>7WT*3=JPXU7?:$IK:0R]6K[%4
M8:I-^.DI;>2NS@PJF'N5NY*(K1IQY6]/::>*M#2#MO(S),UMO&WK0^)Z0Y-]
M2'1 ^/9(-N-XY)SWH$B#W9*6W:/6IOIA$P@0O"/%7.?]L)[.7<>DPSUBV1:3
M#_E@#^65"5P(\AO7=6;)98%?H6##[T%;FI+X@=="C#L4=@]E)9G92N8RGCWZ
MG" 6C!JZ8GPO5AH2I9$XO$]/=+&87B=D)5&2PA+;47IBN-@O(#038#0P5Y5
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M! 8&RUPS4'K;S&(=CH$3X!U0BSR1T5&P[NP>#.XCR+_I1D-3Z$':H=[!+Q=
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M@P"3I$?4'YX[0OWE/IL%W^D2+=IID[S%_0_OHT7]=,T&%.+V54:<>FK/-)C
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M+M8\=[][PB-]U6XG/*@< BH=.R!-/7Y0($<Y;X+S+ @$EC+]8^(:5<EB,>^
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M;.:.*24!X6'SU9)!AB&M]<+";(V3Y-TVBU.2P0.1H7++@M5BG86:)" 6;+X
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M2!;OGC^2)6%BW<$=V>7O^($>6JXP>L2ZOGKK71WS8JXS, @(#W4+7>IEJ%H
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MULO"ZNE[BT"#@)NP@G2CQ&(D8JD6<N>N]4!F]@Q=#602'/9K"D+C@IO)'L$
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MJP?VR%]02P$"% ,4    "  PB-96UE5.[HI?  #2%0( "@
M@ $     97@Q,"TQ+FAT;5!+ 0(4 Q0    ( #"(UE:\4>![-B(  *;0   *
M              "  ;)?  !E>#$P+3(N:'1M4$L! A0#%     @ ,(C65N^;
MA/<.*0  K"P!  H              ( !$((  &5X,3 M,RYH=&U02P$"% ,4
M    "  PB-96/&!/F=HN  "#4 $ "@              @ %&JP  97@Q,"TT
M+FAT;5!+ 0(4 Q0    ( #"(UE94PM(K2@D  % G   *              "
M 4C:  !E>#DY+3$N:'1M4$L! A0#%     @ ,(C65H.X(U\!&P  R,$   L
M             ( !NN,  &9O<FTX+6LN:'1M4$L! A0#%     @ ,(C65F4=
M"-?X P  N@\  !$              ( !Y/X  &QF;60M,C R,S V,C N>'-D
M4$L! A0#%     @ ,(C65JB?#2L)"0  K6@  !4              ( !"P,!
M &QF;60M,C R,S V,C!?9&5F+GAM;%!+ 0(4 Q0    ( #"(UE:YST9:!0P
M &V0   5              "  4<, 0!L9FUD+3(P,C,P-C(P7VQA8BYX;6Q0
M2P$"% ,4    "  PB-964IZY,T\(  !'8P  %0              @ %_& $
K;&9M9"TR,#(S,#8R,%]P<F4N>&UL4$L%!@     *  H 60(   $A 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
